Chronic kidney disease progression in patients with autosomal dominant polycystic kidney disease

array:21 ["pii" => "X2013251412000914" "issn" => "20132514" "doi" => "10.3265/Nefrologia.pre2011.Dec.11177" "estado" => "S300" "fechaPublicacion" => "2012-03-01" "documento" => "article" "licencia" => "http://www.elsevier.com/open-access/userlicense/1.0/" "subdocumento" => "fla" "cita" => "Nefrologia (English Version). 2012;32:197-205" "abierto" => array:3 [ "ES" => true "ES2" => true "LATM" => true ] "gratuito" => true "lecturas" => array:2 [ "total" => 7176 "formatos" => array:3 [ "EPUB" => 284 "HTML" => 6160 "PDF" => 732 ] ] "Traduccion" => array:1 [ "es" => array:17 [ "pii" => "X0211699512000917" "issn" => "02116995" "doi" => "10.3265/Nefrologia.pre2011.Dec.11177" "estado" => "S300" "fechaPublicacion" => "2012-03-01" "documento" => "article" "licencia" => "http://www.elsevier.com/open-access/userlicense/1.0/" "subdocumento" => "fla" "cita" => "Nefrologia. 2012;32:197-205" "abierto" => array:3 [ "ES" => true "ES2" => true "LATM" => true ] "gratuito" => true "lecturas" => array:2 [ "total" => 10613 "formatos" => array:3 [ "EPUB" => 253 "HTML" => 9745 "PDF" => 615 ] ] "es" => array:12 [ "idiomaDefecto" => true "titulo" => "Progresión de la enfermedad renal crónica en pacientes con enfermedad poliquística autosómica dominante" "tienePdf" => "es" "tieneTextoCompleto" => "es" "tieneResumen" => array:2 [ 0 => "es" 1 => "en" ] "paginas" => array:1 [ 0 => array:2 [ "paginaInicial" => "197" "paginaFinal" => "205" ] ] "titulosAlternativos" => array:1 [ "en" => array:1 [ "titulo" => "Chronic kidney disease progression in patients with autosomal dominant polycystic kidney disease" ] ] "contieneResumen" => array:2 [ "es" => true "en" => true ] "contieneTextoCompleto" => array:1 [ "es" => true ] "contienePdf" => array:1 [ "es" => true ] "resumenGrafico" => array:2 [ "original" => 0 "multimedia" => array:8 [ "identificador" => "fig1" "etiqueta" => "Tab. 1" "tipo" => "MULTIMEDIAFIGURA" "mostrarFloat" => true "mostrarDisplay" => false "copyright" => "Elsevier España" "figura" => array:1 [ 0 => array:4 [ "imagen" => "11177_108_21581_es_11177_t1.jpg" "Alto" => 257 "Ancho" => 569 "Tamanyo" => 84616 ] ] "descripcion" => array:1 [ "es" => "Características basales de los pacientes (variables cualitativas)" ] ] ] "autores" => array:1 [ 0 => array:2 [ "autoresLista" => "Nayara Panizo, Marian Goicoechea, Soledad García de Vinuesa, David Arroyo, Claudia Yuste, Abraham Rincón, Ursula Verdalles, Caridad Ruiz-Caro, Borja Quiroga, José Luño" "autores" => array:16 [ 0 => array:2 [ "nombre" => "Nayara" "apellidos" => "Panizo" ] 1 => array:2 [ "nombre" => "Nayara" "apellidos" => "Panizo" ] 2 => array:2 [ "nombre" => "Marian" "apellidos" => "Goicoechea" ] 3 => array:2 [ "nombre" => "Marian" "apellidos" => "Goicoechea" ] 4 => array:2 [ "nombre" => "Soledad" "apellidos" => "García de Vinuesa" ] 5 => array:2 [ "nombre" => "David" "apellidos" => "Arroyo" ] 6 => array:2 [ "nombre" => "David" "apellidos" => "Arroyo" ] 7 => array:2 [ "nombre" => "Claudia" "apellidos" => "Yuste" ] 8 => array:2 [ "nombre" => "Claudia" "apellidos" => "Yuste" ] 9 => array:2 [ "nombre" => "Abraham" "apellidos" => "Rincón" ] 10 => array:2 [ "nombre" => "Abraham" "apellidos" => "Rincón" ] 11 => array:2 [ "nombre" => "Ursula" "apellidos" => "Verdalles" ] 12 => array:2 [ "nombre" => "Ursula" "apellidos" => "Verdalles" ] 13 => array:2 [ "nombre" => "Caridad" "apellidos" => "Ruiz-Caro" ] 14 => array:2 [ "nombre" => "Borja" "apellidos" => "Quiroga" ] 15 => array:2 [ "nombre" => "José" "apellidos" => "Luño" ] ] ] ] ] "idiomaDefecto" => "es" "Traduccion" => array:1 [ "en" => array:9 [ "pii" => "X2013251412000914" "doi" => "10.3265/Nefrologia.pre2011.Dec.11177" "estado" => "S300" "subdocumento" => "" "abierto" => array:3 [ "ES" => true "ES2" => true "LATM" => true ] "gratuito" => true "lecturas" => array:1 [ "total" => 0 ] "idiomaDefecto" => "en" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/X2013251412000914?idApp=UINPBA000064" ] ] "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/X0211699512000917?idApp=UINPBA000064" "url" => "/02116995/0000003200000002/v0_201502091353/X0211699512000917/v0_201502091353/es/main.assets" ] ] "itemSiguiente" => array:17 [ "pii" => "X2013251412000906" "issn" => "20132514" "doi" => "10.3265/Nefrologia.pre2011.Dec.11223" "estado" => "S300" "fechaPublicacion" => "2012-03-01" "documento" => "article" "licencia" => "http://www.elsevier.com/open-access/userlicense/1.0/" "subdocumento" => "fla" "cita" => "Nefrologia (English Version). 2012;32:206-12" "abierto" => array:3 [ "ES" => true "ES2" => true "LATM" => true ] "gratuito" => true "lecturas" => array:2 [ "total" => 11240 "formatos" => array:3 [ "EPUB" => 305 "HTML" => 10038 "PDF" => 897 ] ] "en" => array:12 [ "idiomaDefecto" => true "titulo" => "Congestive heart failure in patients with advanced chronic kidney disease: association with pre-emptive vascular access placement" "tienePdf" => "en" "tieneTextoCompleto" => "en" "tieneResumen" => array:2 [ 0 => "es" 1 => "en" ] "paginas" => array:1 [ 0 => array:2 [ "paginaInicial" => "206" "paginaFinal" => "212" ] ] "titulosAlternativos" => array:1 [ "es" => array:1 [ "titulo" => "Insuficiencia cardíaca en la enfermedad renal crónica avanzada: relación con el acceso vascular" ] ] "contieneResumen" => array:2 [ "es" => true "en" => true ] "contieneTextoCompleto" => array:1 [ "en" => true ] "contienePdf" => array:1 [ "en" => true ] "resumenGrafico" => array:2 [ "original" => 0 "multimedia" => array:8 [ "identificador" => "fig1" "etiqueta" => "Tab. 1" "tipo" => "MULTIMEDIAFIGURA" "mostrarFloat" => true "mostrarDisplay" => false "copyright" => "Elsevier España" "figura" => array:1 [ 0 => array:4 [ "imagen" => "11223_16025_27344_en_t111223en.jpg" "Alto" => 1959 "Ancho" => 2170 "Tamanyo" => 1348742 ] ] "descripcion" => array:1 [ "en" => "Clinical and laboratory parameters for all patients and each sub-group according to the presence or absence of congestive heart failure" ] ] ] "autores" => array:1 [ 0 => array:2 [ "autoresLista" => "Rocío Martínez Gallardo, Rocío Martínez-Gallardo, Flavio Ferreira Morong, Flavio Ferreira-Morong, Guadalupe García Pino, Guadalupe García-Pino, Isis Cerezo Arias, Isis Cerezo-Arias, Román Hernández Gallego, Román Hernández-Gallego, Francisco Caravaca Magariños" "autores" => array:12 [ 0 => array:2 [ "nombre" => "Rocío" "apellidos" => "Martínez Gallardo" ] 1 => array:2 [ "nombre" => "Rocío" "apellidos" => "Martínez-Gallardo" ] 2 => array:2 [ "nombre" => "Flavio" "apellidos" => "Ferreira Morong" ] 3 => array:2 [ "nombre" => "Flavio" "apellidos" => "Ferreira-Morong" ] 4 => array:2 [ "nombre" => "Guadalupe" "apellidos" => "García Pino" ] 5 => array:2 [ "nombre" => "Guadalupe" "apellidos" => "García-Pino" ] 6 => array:2 [ "nombre" => "Isis" "apellidos" => "Cerezo Arias" ] 7 => array:2 [ "nombre" => "Isis" "apellidos" => "Cerezo-Arias" ] 8 => array:2 [ "nombre" => "Román" "apellidos" => "Hernández Gallego" ] 9 => array:2 [ "nombre" => "Román" "apellidos" => "Hernández-Gallego" ] 10 => array:2 [ "nombre" => "Francisco" "apellidos" => "Caravaca Magariños" ] 11 => array:2 [ "nombre" => "Francisco" "apellidos" => "Caravaca" ] ] ] ] ] "idiomaDefecto" => "en" "Traduccion" => array:1 [ "es" => array:9 [ "pii" => "X0211699512000909" "doi" => "10.3265/Nefrologia.pre2011.Dec.11223" "estado" => "S300" "subdocumento" => "" "abierto" => array:3 [ "ES" => true "ES2" => true "LATM" => true ] "gratuito" => true "lecturas" => array:1 [ "total" => 0 ] "idiomaDefecto" => "es" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/X0211699512000909?idApp=UINPBA000064" ] ] "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/X2013251412000906?idApp=UINPBA000064" "url" => "/20132514/0000003200000002/v0_201502091616/X2013251412000906/v0_201502091617/en/main.assets" ] "itemAnterior" => array:17 [ "pii" => "X2013251412000922" "issn" => "20132514" "doi" => "10.3265/Nefrologia.pre2011.Nov.10962" "estado" => "S300" "fechaPublicacion" => "2012-03-01" "documento" => "article" "licencia" => "http://www.elsevier.com/open-access/userlicense/1.0/" "subdocumento" => "fla" "cita" => "Nefrologia (English Version). 2012;32:187-96" "abierto" => array:3 [ "ES" => true "ES2" => true "LATM" => true ] "gratuito" => true "lecturas" => array:2 [ "total" => 6713 "formatos" => array:3 [ "EPUB" => 276 "HTML" => 5565 "PDF" => 872 ] ] "en" => array:12 [ "idiomaDefecto" => true "titulo" => "High doses of irbesartan offer long-term kidney protection in cases of established diabetic nephropathy" "tienePdf" => "en" "tieneTextoCompleto" => "en" "tieneResumen" => array:2 [ 0 => "es" 1 => "en" ] "paginas" => array:1 [ 0 => array:2 [ "paginaInicial" => "187" "paginaFinal" => "196" ] ] "titulosAlternativos" => array:1 [ "es" => array:1 [ "titulo" => "Efectos renoprotectores a largo plazo de dosis altas de irbesartán en la nefropatía diabética establecida" ] ] "contieneResumen" => array:2 [ "es" => true "en" => true ] "contieneTextoCompleto" => array:1 [ "en" => true ] "contienePdf" => array:1 [ "en" => true ] "resumenGrafico" => array:2 [ "original" => 0 "multimedia" => array:8 [ "identificador" => "fig1" "etiqueta" => "Tab. 1" "tipo" => "MULTIMEDIAFIGURA" "mostrarFloat" => true "mostrarDisplay" => false "copyright" => "Elsevier España" "figura" => array:1 [ 0 => array:4 [ "imagen" => "10962_16025_27957_en_t1_10962i.jpg" "Alto" => 654 "Ancho" => 1083 "Tamanyo" => 827943 ] ] "descripcion" => array:1 [ "en" => "Treatments administered over the course of the study period" ] ] ] "autores" => array:1 [ 0 => array:2 [ "autoresLista" => "Silvia Ros Ruiz, Silvia Ros-Ruiz, Pedro Aranda Lara, Pedro Aranda-Lara, Juan Carlos Fernández, Juan C. Fernández, Maria Dolores Martínez Esteban, M. Dolores Martínez-Esteban, Cristina Jironda, Pilar Hidalgo, Domingo Hernández Marrero, Domingo Hernández-Marrero" "autores" => array:12 [ 0 => array:2 [ "nombre" => "Silvia" "apellidos" => "Ros Ruiz" ] 1 => array:2 [ "nombre" => "Silvia" "apellidos" => "Ros-Ruiz" ] 2 => array:2 [ "nombre" => "Pedro" "apellidos" => "Aranda Lara" ] 3 => array:2 [ "nombre" => "Pedro" "apellidos" => "Aranda-Lara" ] 4 => array:2 [ "nombre" => "Juan Carlos" "apellidos" => "Fernández" ] 5 => array:2 [ "nombre" => "Juan C." "apellidos" => "Fernández" ] 6 => array:2 [ "nombre" => "Maria Dolores" "apellidos" => "Martínez Esteban" ] 7 => array:2 [ "nombre" => "M. Dolores" "apellidos" => "Martínez-Esteban" ] 8 => array:2 [ "nombre" => "Cristina" "apellidos" => "Jironda" ] 9 => array:2 [ "nombre" => "Pilar" "apellidos" => "Hidalgo" ] 10 => array:2 [ "nombre" => "Domingo" "apellidos" => "Hernández Marrero" ] 11 => array:2 [ "nombre" => "Domingo" "apellidos" => "Hernández-Marrero" ] ] ] ] ] "idiomaDefecto" => "en" "Traduccion" => array:1 [ "es" => array:9 [ "pii" => "X0211699512000925" "doi" => "10.3265/Nefrologia.pre2011.Nov.10962" "estado" => "S300" "subdocumento" => "" "abierto" => array:3 [ "ES" => true "ES2" => true "LATM" => true ] "gratuito" => true "lecturas" => array:1 [ "total" => 0 ] "idiomaDefecto" => "es" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/X0211699512000925?idApp=UINPBA000064" ] ] "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/X2013251412000922?idApp=UINPBA000064" "url" => "/20132514/0000003200000002/v0_201502091616/X2013251412000922/v0_201502091616/en/main.assets" ] "en" => array:15 [ "idiomaDefecto" => true "titulo" => "Chronic kidney disease progression in patients with autosomal dominant polycystic kidney disease" "tieneTextoCompleto" => true "paginas" => array:1 [ 0 => array:2 [ "paginaInicial" => "197" "paginaFinal" => "205" ] ] "autores" => array:1 [ 0 => array:3 [ "autoresLista" => "Nayara Panizo, Marian Goicoechea, Soledad García de Vinuesa, David Arroyo, Claudia Yuste, Abraham Rincón, Ursula Verdalles, Caridad Ruiz-Caro, Borja Quiroga, José Luño" "autores" => array:16 [ 0 => array:4 [ "nombre" => "Nayara" "apellidos" => "Panizo" "email" => array:1 [ 0 => "nayapanizo@gmail.com" ] "referencia" => array:1 [ 0 => array:2 [ "etiqueta" => "a" "identificador" => "affa" ] ] ] 1 => array:4 [ "nombre" => "Nayara" "apellidos" => "Panizo" "email" => array:1 [ 0 => "nayapanizo@gmail.com" ] "referencia" => array:1 [ 0 => array:2 [ "etiqueta" => "b" "identificador" => "affb" ] ] ] 2 => array:3 [ "nombre" => "Marian" "apellidos" => "Goicoechea" "referencia" => array:1 [ 0 => array:2 [ "etiqueta" => "a" "identificador" => "affa" ] ] ] 3 => array:3 [ "nombre" => "Marian" "apellidos" => "Goicoechea" "referencia" => array:1 [ 0 => array:2 [ "etiqueta" => "b" "identificador" => "affb" ] ] ] 4 => array:3 [ "nombre" => "Soledad" "apellidos" => "García de Vinuesa" "referencia" => array:1 [ 0 => array:2 [ "etiqueta" => "b" "identificador" => "affb" ] ] ] 5 => array:3 [ "nombre" => "David" "apellidos" => "Arroyo" "referencia" => array:1 [ 0 => array:2 [ "etiqueta" => "a" "identificador" => "affa" ] ] ] 6 => array:3 [ "nombre" => "David" "apellidos" => "Arroyo" "referencia" => array:1 [ 0 => array:2 [ "etiqueta" => "b" "identificador" => "affb" ] ] ] 7 => array:3 [ "nombre" => "Claudia" "apellidos" => "Yuste" "referencia" => array:1 [ 0 => array:2 [ "etiqueta" => "a" "identificador" => "affa" ] ] ] 8 => array:3 [ "nombre" => "Claudia" "apellidos" => "Yuste" "referencia" => array:1 [ 0 => array:2 [ "etiqueta" => "b" "identificador" => "affb" ] ] ] 9 => array:3 [ "nombre" => "Abraham" "apellidos" => "Rincón" "referencia" => array:1 [ 0 => array:2 [ "etiqueta" => "a" "identificador" => "affa" ] ] ] 10 => array:3 [ "nombre" => "Abraham" "apellidos" => "Rincón" "referencia" => array:1 [ 0 => array:2 [ "etiqueta" => "b" "identificador" => "affb" ] ] ] 11 => array:3 [ "nombre" => "Ursula" "apellidos" => "Verdalles" "referencia" => array:1 [ 0 => array:2 [ "etiqueta" => "a" "identificador" => "affa" ] ] ] 12 => array:3 [ "nombre" => "Ursula" "apellidos" => "Verdalles" "referencia" => array:1 [ 0 => array:2 [ "etiqueta" => "b" "identificador" => "affb" ] ] ] 13 => array:3 [ "nombre" => "Caridad" "apellidos" => "Ruiz-Caro" "referencia" => array:1 [ 0 => array:2 [ "etiqueta" => "c" "identificador" => "affc" ] ] ] 14 => array:3 [ "nombre" => "Borja" "apellidos" => "Quiroga" "referencia" => array:1 [ 0 => array:2 [ "etiqueta" => "b" "identificador" => "affb" ] ] ] 15 => array:3 [ "nombre" => "José" "apellidos" => "Luño" "referencia" => array:1 [ 0 => array:2 [ "etiqueta" => "b" "identificador" => "affb" ] ] ] ] "afiliaciones" => array:3 [ 0 => array:3 [ "entidad" => "Servicio de Nefrología, Hospital General Universitario Gregorio Marañón, Madrid, Spain, " "etiqueta" => "a" "identificador" => "affa" ] 1 => array:3 [ "entidad" => "Servicio de Nefrología, Hospital General Universitario Gregorio Marañón, Madrid, " "etiqueta" => "b" "identificador" => "affb" ] 2 => array:3 [ "entidad" => " Clínica Dialcentro, Madrid, " "etiqueta" => "c" "identificador" => "affc" ] ] ] ] "titulosAlternativos" => array:1 [ "es" => array:1 [ "titulo" => "Progresión de la enfermedad renal crónica en pacientes con enfermedad poliquística autosómica dominante" ] ] "resumenGrafico" => array:2 [ "original" => 0 "multimedia" => array:8 [ "identificador" => "fig1" "etiqueta" => "Tab. 1" "tipo" => "MULTIMEDIAFIGURA" "mostrarFloat" => true "mostrarDisplay" => false "copyright" => "Elsevier España" "figura" => array:1 [ 0 => array:4 [ "imagen" => "11177_16025_26764_en_t1_11177.jpg" "Alto" => 477 "Ancho" => 1063 "Tamanyo" => 744603 ] ] "descripcion" => array:1 [ "en" => "Baseline patient characteristics (qualitative variables)" ] ] ] "textoCompleto" => "INTRODUCTION Autosomal dominant polycystic kidney disease (ADPKD) is one of the most common hereditary diseases observed and the most frequent genetic cause of chronic kidney disease (CKD).1-3 This disease affects one out of every 800-1000 people in the global population, and constitutes the aetiology for terminal chronic kidney disease (TCKD) in 5%-10% of patients on extra-renal purification programmes.4Despite the importance of this health issue, it was not been the subject of much research until recent years, when several studies were performed with the objective of identifying predictive factors for a rapid progression of renal disease.5-7 Some of these factors can be modified by using different therapeutic interventions that are currently under study, such as tolvaptan,8,9 m-TOR (mammalian target of rapamycin) inhibitors,10 somatostatin analogues,11 and even rosiglitazone,12 which have been used successfully in animal models.Among the factors that have been identified in the progression of ADPKD, the most important one is hypertension,8,14 but other possible factors for the progression of disease have been identified, such as African American race,15 male sex, haematuria, proteinuria, renal cyst volume, and polycystin 1 (PKD1) vs polycystin 2 (PKD2) mutations.1The objective of our study was to perform a retrospective analysis of the factors that influence the progression of chronic renal failure in incident patients with ADPKD treated at our department throughout the last 13 years.Our study, which dealt with patients at a single centre and thus a small sample size, stands out for the long follow-up period that, although was retrospective in nature, has been surpassed by only a few studies published to date. In contrast to other studies, the importance of systolic (SBP) as opposed to diastolic (DBP) blood pressure stands out as a factor for the progression of renal failure in these patients. Additionally, we have underlined the prognostic importance of age at diagnosis as a possible variable suggestive of which type of genetic mutation is present. As such, our study provides a simple and practical focus for the evaluation of the risk of rapid progression towards TCKD. We have also evaluated the role of other factors of progression such as dyslipidemia and hyperuricemia, which have been poorly studied until now. MATERIAL AND METHOD We included a total of 101 patients that were monitored at our clinic from 1997 to the present. Patients had been diagnosed with ADPKD based on standardised radiological criteria.16 Patients with ADPKD with less than two visits to our practice were excluded, whether because the patient abandoned the follow-up protocol or when a renal event occurred within the first year after diagnosis.At each visit, we collected demographical variables, SBP and DBP values, concomitant medications, haemoglobin, creatinine (Cr), uric acid, total cholesterol, HDL-cholesterol, LDL-cholesterol, triglycerides, calcium, phosphorous, parathyroid hormone (PTH), proteinuria, and haematuria. Biochemical variables were measured using standard methods. PTH was measured using IRMA (intact 10-60pg/ml molecule, Allegro Nichols). Albuminuria was measured in 24-hour urine samples using immunonephelometric methods. Haematuria was defined in urine sediments as the presence of more than three red blood cells per microscopic field in at least two of three correctly collected samples.17 Kidney size (cm) was measured using renal ultrasound. Although each patient underwent several ultrasounds throughout the follow-up period, only baseline values were taken into account for the analysis, both for the largest renal cyst and maximum kidney diameter in centimetres. Since this was a retrospective analysis, we did not have an initially standardised methodology for taking measurements, and multiple professionals performed the procedures. Over the 13 years of the study, different radiologists evaluated the ultrasounds (three different doctors evaluated the majority of images). Inter and intra-observer variability was not taken into account.Blood pressure (BP) was measured using an automatic sphygmanometer in accordance with the recommendations of the Spanish Society of Hypertension.18 Patients were considered hypertensive when SBP and DBP were equal to or greater than 140mm Hg and 90mm Hg, respectively, or if they were receiving anti-hypertensive drugs. The treatment objective was set at 130/80mm Hg, in accordance with the recommendations of the seventh report of the JNC (Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure).19Dyslipidemia was defined as total cholesterol greater than 200mg/dl and LDL-cholesterol greater than 130mg/dl, in accordance with the European guidelines for cardiovascular prevention,20 or if the patient was receiving lipid lowering treatment.Renal function was evaluated as estimated glomerular filtration rate (eGFR) using the CKD-EPI formula.21We analysed the progression renal failure using the following two methods:1) Based on the appearance of a renal event, defined as a 50% reduction in eGFR as measured by CKD-EPI from the initial values from the outpatient visit and/or entrance to dialysis.2) Based on mean change in eGFR/year. According to the decrease in eGFR/year above or below the mean, we defined two different groups: group A: patients with a fast progression of CKD; and group B: patients with a normal progression of CKD.Patients diagnosed with ADPKD were included in the study from the moment of their first visit with a nephrologist, considering all measurements from this consultation as baseline values, until a renal event occurred. Data were compiled on an annual basis, with the number of visits ranging between 1 and 10. The longest follow-up period lasted 13 years. The median follow-up time was 69 (35-128) months.Values are expressed as mean ± SD (standard deviation) or median (interquartile range) if the variables did not follow a normal distribution. We used the Kolmogorov-Smirnov test to evaluate normal distribution for the different parameters assessed. For the analysis of differences between patients that suffered a renal event and those that did not, we used chi-square tests for qualitative variables and Student’s t-tests or Mann-Whitney U-tests for quantitative variables with a normal distribution or non-Gaussian distribution, respectively. We assumed that a difference was statistically significant when P<.05.We performed a multivariate linear regression analysis using the variables that influenced annual change in eGFR. The prognostic value of the predictive factors for the appearance of renal events or rapid progression towards CKD was evaluated using a Cox regression multivariate model. We introduced all covariates into the multivariate model that had a predictive power for renal events or rapid progression in the univariate model with a P<.01. The regression coefficients and their SD were calculated using SPSS software, version 16.0 (Chicago, IL). RESULTS Our study included a total of 101 patients, 44 of which were male and 57 of which were female. The mean age was 43.5±17.2 years. The baseline characteristics for these patients are collected in Tables 1 and 2.Figure 1 displays the evolution of eGFR (ml/min/1.73m2) in all patients and in the two different groups of disease progression.Figure 2 displays the evolution of SBP and DBP values throughout the follow-up period. A total of 41.4% of patients were already receiving antihypertensive treatment with angiotensin-converting enzyme (ACE) inhibitors or angiotensin receptor blockers (ARB) at the start of the follow-up period. Throughout the study period, 16.9% of patients started treatment with ACE inhibitors and 15.7% with ARB, such that 74% of patients received antihypertensive treatment over the course of the study.During the study period, 31 patients suffered a renal event. The median time of follow-up between the baseline visit and the event was 102 months (range: 53-131 months). The univariate analysis showed that patients that suffered a renal event had higher baseline SBP, DBP, uric acid, total cholesterol, LDL-cholesterol, baseline Cr, proteinuria, and larger kidney size (Table 3). There were significant differences in mean initial eGFR between the two groups, with 82.5±34.2ml/min/1.73m2 in the group of patients that did not suffer a renal event, and 59.8±22.7ml/min/1.73m2 in the group that did (P=.01). We observed no significant differences between groups for variables such as haematocrit, calcium, phosphorous, HDL-cholesterol, and triglycerides (results not shown in the table).In the Cox regression model adjusted for baseline renal function, proteinuria, uric acid, BP, and cholesterol, SBP was the variable that maintained its predictive value for a renal event.The mean annual change in GFR in the overall group of patients was -3.52±7.3ml/min/1.73m2. In the multivariate linear regression model, change in GFR was independently correlated with SBP (β=-6.7x10-2, P=.03).We identified 49 patients with rapid disease progression (decrease >3.52ml/min/1.73m2): group A, and 52 patients with normal progression (less than 3.52ml/min/1.73m2): group B. There were no significant differences between the two groups in terms of initial eGFR, which was 74.1±32.7ml/min/1.73m2 in the group with normal progression, and 76.7±32.6ml/min/1.73m2 in the rapid progression group (P>.05). Group A patients had higher baseline SBP and proteinuria (Table 4). The logistic regression analysis revealed that the predictive variable for a rapid disease progression was still SBP, with the addition of a younger age at the first consultation, regardless of proteinuria, sex, initial renal function, and DBP (Table 5). DISCUSSION The primary result of our study, with a cohort of stable patients diagnosed with ADPKD and evaluated in nephrological consultations, was the confirmation that systolic arterial hypertension and a younger age at diagnosis are the most important factors that influence the long-term progression of renal failure.Many recent studies on ADPKD have focused on the importance of renal volume as a determining factor in the deterioration of renal function, which advances parallel to the increase in cyst sizes.22 There are also other studies that correlate clinical and biochemical parameters with kidney size and glomerular filtration rate.5 However, there are few examples in the literature that correlate a patient’s baseline clinical characteristics with long-term clinical evolution as our study has. Recently, a retrospective cohort study was published with a follow-up period of 22 years, including 194 patients with ADPKD, which analysed the influence of mutation type on clinical characteristics and the development of renal events.23 Cyst growth appears to be one of the most important factors in determining the progression of CKD in these patients. As such, in many clinical trials focusing on therapeutic interventions, cyst growth has been used as the reference marker for identifying patients that could benefit from treatment.5,24 However, one of the most reliable methods for measuring renal structure and volume, standard magnetic resonance,25 is an expensive method that is not available in all hospitals and requires a large amount of time from the radiologist. A similar pattern occurs in computed tomography, which has been employed in volumetric measurements, with good correlation with total renal volume, renal cyst volume, and decrease in eGFR.26,27 Some authors have indicated that the deterioration in renal function does not depend on cyst volume as much as on the amount of intermediate tissue in polycystic kidneys measured by computed tomography.28 Other methods of measurement such as ultrasound do not provide as good a correlation for renal function,27 and so we need other variables from our clinical practice that aid in identifying patients that would benefit from early treatment. In our study, we evaluated kidney size using ultrasound, which was an imprecise method, taking into account that the measurements were taken by various radiologists. Although the univariate analysis revealed a difference in kidney size between patients that had a renal event and those that did not, this variable did not retain its predictive value when other parameters were adjusted for.As such, in routine clinical practice, it would be very beneficial to have access to markers, aside from cyst growth, that would identify patients who, starting at an early age, will suffer a rapid progression in their kidney disease, and as such will be candidates for more aggressive therapeutic options, when sufficient evidence exists in the literature to support their use.Arterial hypertension is a common clinical manifestation in patients with ADPKD. A recent demographic study performed in Turkey with 1139 patients with ADPKD identified this as the most common clinical manifestation in these patients, as it was present in 76% of cases.29 It commonly occurs early on, before the appearance of deteriorated renal function in 60% of cases.30 Several studies have related hypertension with the speed of progression in renal disease. One retrospective study with 94 patients compared rapid progression with slow progression patients, finding that those who progressed faster had a higher incidence of hypertension, haematuria, proteinuria, and urinary infections.31 Another study points out that hypertensive patients with ADPKD have worse renal function than normotensive patients, with an added increase in cardiovascular risk.32 There have also been studies showing a lower mortality rate33 and a progressive delay in the age at which these patients reach TCKD, relating this to a progressively better control of blood pressure levels in recent years,1,34 especially from the use of ACE inhibitors and ARB, although no differences have been found between the two drugs in controlling BP and Cr values in these patients.35 In a recently published study in Spain, kidney size was correlated with a pathological profile involving BP as measured in outpatient monitoring programmes, highlighting a greater variability in BP, especially diastolic, and lower pulse pressure with greater kidney size, as measured using ultrasound, even in a stage of pre-hypertension.36 Our study corroborated these findings, with the novel result that it is SBP, not DBP, that maintains its independent predictive value for the rapid progression of kidney disease, which is in agreement with the results from other studies, such as the report by Cadnapaphornchai et al.,37 which analysed the association between renal volume, SBP and DBP, and left ventricular mass index in patients with ADPKD. As in our case, they detected an association between both BP variables and renal volume in the univariate analysis, but only SBP remained after adjusting for age and sex in the multivariate analysis.The percentage of patients that were already receiving treatment with renin-angiotensin-aldosterone system (RAAS) blockers at the start of treatment was 41.4%; 32.6% started treatment with these drugs during the follow-up period. In total, 74% received treatment with RAAS blockers over the study period. We observed no differences between patients receiving this treatment and those that did not, whether in terms of the appearance of renal events or the speed of progression. However, it is well known that control of BP levels, especially systolic, is a fundamental factor for slowing the progression of kidney disease, not only in ADPKD, but in CKD in general, as demonstrated by several studies.38-40 In the specific case of ADPKD, the HALT study is currently under way, with the goal of elucidating the potential benefit of strict BP control using RAAS blockers in slowing the progression of TCKD.41In the univariate analysis, we found that patients with a renal event or rapid disease progression had higher initial proteinuria values than those with a slow disease progression/absence of renal events. However, this variable did not maintain its predictive value in the Cox regression analysis, despite the fact that proteinuria is a known factor for the progression of kidney disease.42 This fact was probably due to the low values of proteinuria displayed by our patients (median: 19.75; IQR: 0-58.5), as proteinuria is an uncharacteristic manifestation of this disease.Our second notable finding was that younger patients had a higher rate of decrease in eGFR. These results concur with those from Torres et al., who showed that a younger age at diagnosis is associated with a greater increase in total renal volume, and this, in turn, is correlated with a greater rate of decrease in glomerular filtration rate.5 Although we did not perform a genetic study, we can put this finding in the context of the higher probability that these patients have a mutation on the PKD1 gene, which tends to produce a greater pathological repercussion and earlier deterioration in renal function.43,44 These results are supported by those from the genetic study by Torra et al., which found that, in patients with ADPKD that had not reached TCKD by the age of 63 years, the prevalence of PKD2 mutations was three times higher than the estimated proportion for the general population with ADPKD.45 Other studies also coincide on the finding that, in families diagnosed with the disease in which at least one member reached TCKD at an age younger than 55, there is a high probability that the mutation is on the PKD1 gene.46Our results also demonstrate the importance of controlling other cardiovascular risk factors, such as cholesterol and uric acid, both for the progression of CKD in patients with ADPKD and in other renal pathologies. Although these parameters do not independently influence the progression of renal failure, they do appear to be important and controllable variables in the appearance of renal events in the univariate analysis. Several studies have suggested that ADPKD produces an increase in uric acid levels associated with decreased renal function,47 but there are no data regarding the influence of uric acid levels on the progression of the kidney disease in this particular case. However, in recent years, the relationship between hyperuricemia and the progression of CKD has been investigated,48,49 and recently the use of uric acid lowering drugs (allopurinol) has been shown to reduce disease progression.50 As regards lipid control, several studies have indicated that lower HDL-cholesterol levels are correlated with increased deterioration of renal function,5 although we have not found data in the literature that show the influence of LDL-cholesterol levels on renal function in patients with ADPKD. Even so, the fact that patients with worse cholesterol levels have more renal events supports the hypothesis held by some trials that have attempted to show that renal function in these patients could be improved by using statins, through an increase in renal plasma flow derived from improved endothelial function.51Our study is not without its limitations. The primary limitation in our case was that, while the study design was a prospective, longitudinal type, the data collection was retrospective, with the inherent drawbacks from the point of view of data analysis, and so we can only show evidence of an association between systolic hypertension and increased disease progression. Additionally, the sample was not sufficiently large due to the fact that our data were derived from one single centre. However, despite the small sample size, the extremely long follow-up period has been surpassed by only a few isolated studies available in the medical literature,1,33,34 which bolsters the validity of our results. We should also point out the limitations of the absence of a genetic analysis, along with the use of renal ultrasound instead of a computed tomography or nuclear magnetic resonance for the evaluation of initial renal volume.We can conclude that a younger age at diagnosis and higher SBP values are the two factors associated with a greater progression of renal disease in our patients with ADPKD. These two variables, which are easily measured, allow us to detect patients that have a high probability of a faster progression towards TCKD in centres that do not have easy access to genetic analyses or magnetic resonance. This in turn provides the possibility of selecting these patients as candidates for possible future treatments that show long-term advantages in slowing the progression towards the need for extra-renal purification. Interventional studies are needed to establish the potential benefit of controlling SBP values, cholesterol, and uric acid in slowing the progression towards TCKD in these patients. Conflicts of Interest The authors have no potential conflicts of interest related to the content of this article to declare.<a href="grande/11177_16025_26764_en_t1_11177.jpg" class="elsevierStyleCrossRefs"><img src="11177_16025_26764_en_t1_11177.jpg" alt="Baseline patient characteristics (qualitative variables)"></img></a>Table 1. Baseline patient characteristics (qualitative variables)<a href="grande/11177_16025_26765_en_t2_11177.jpg" class="elsevierStyleCrossRefs"><img src="11177_16025_26765_en_t2_11177.jpg" alt="Baseline patient characteristics (quantitative variables)"></img></a>Table 2. Baseline patient characteristics (quantitative variables)<a href="grande/11177_16025_26766_en_t3_11177.jpg" class="elsevierStyleCrossRefs"><img src="11177_16025_26766_en_t3_11177.jpg" alt="Predictive factors for renal events. Univariate analysis"></img></a>Table 3. Predictive factors for renal events. Univariate analysis<a href="grande/11177_16025_26768_en_t4_11177.jpg" class="elsevierStyleCrossRefs"><img src="11177_16025_26768_en_t4_11177.jpg" alt="Predictive factors for a rapid progression in kidney disease. Univariate analysis (Student’s t-test)"></img></a>Table 4. Predictive factors for a rapid progression in kidney disease. Univariate analysis (Student’s t-test)<a href="grande/11177_16025_26769_en_t5_11177.jpg" class="elsevierStyleCrossRefs"><img src="11177_16025_26769_en_t5_11177.jpg" alt="Predictive variables for a rapid progression in kidney disease. Logistic regression"></img></a>Table 5. Predictive variables for a rapid progression in kidney disease. Logistic regression<a href="grande/11177_16025_26770_en_f1_11177.jpg" class="elsevierStyleCrossRefs"><img src="11177_16025_26770_en_f1_11177.jpg" alt="Decrease in glomerular filtration rate in all patients and in the two different groups of disease progression"></img></a>Figure 1. Decrease in glomerular filtration rate in all patients and in the two different groups of disease progression<a href="grande/11177_16025_26771_en_f2__11177.jpg" class="elsevierStyleCrossRefs"><img src="11177_16025_26771_en_f2__11177.jpg" alt="Evolution over time of SBP and DBP values during follow-up. Mean (SD)"></img></a>Figure 2. Evolution over time of SBP and DBP values during follow-up. Mean (SD)" "pdfFichero" => "P1-E534-S3437-A11177-EN.pdf" "tienePdf" => true "PalabrasClave" => array:2 [ "es" => array:1 [ 0 => array:4 [ "clase" => "keyword" "titulo" => "Palabras clave" "identificador" => "xpalclavsec438735" "palabras" => array:1 [ 0 => "Enfermedades renales poliquísticas" ] ] ] "en" => array:1 [ 0 => array:4 [ "clase" => "keyword" "titulo" => "Keywords" "identificador" => "xpalclavsec438736" "palabras" => array:1 [ 0 => "Polycystic kidney diseases" ] ] ] ] "tieneResumen" => true "resumen" => array:2 [ "es" => array:1 [ "resumen" => "Objetivos: El objetivo del presente estudio es analizar los factores que influyen en la progresión de la insuficiencia renal crónica en pacientes con enfermedad poliquística autosómica dominante (PQRAD). Material y métodos: Estudiamos a 101 pacientes (edad media: 43,6 ± 17,3, 43,6% varones). La mediana (rango intercuartílico) de seguimiento es de 69 (128-35) meses desde 1997 hasta 2010. Analizamos la progresión de dos formas: 1) tiempo hasta evento renal definido como la reducción del filtrado glomerular estimado (FGe) en un 50% desde la primera visita y/o entrada en diálisis, y 2) cambio medio en el FGe/año. Se recogieron en cada visita datos clínicos y demográficos, presión arterial sistólica (PAS) y diastólica (PAD), medicación concomitante y parámetros analíticos. También se recogió el tamaño renal basal medido por ecografía. Resultados: Treinta y un pacientes tuvieron un evento renal. La mediana de tiempo hasta la aparición del evento es de 102 (131-53) meses. Los pacientes que tuvieron un evento renal tenían basalmente mayor PAS y PAD (p = 0,017 y p = 0,001, respectivamente), mayores niveles de acido úrico (p = 0,041), mayor colesterol LDL (p = 0,001), mayor proteinuria (p = 0,033) y mayor tamaño renal (p = 0,05). El cambio medio de FGe/anual fue de –3,52 ± 7,3 ml/min/1,73 m2, 49 pacientes presentaron un descenso rápido de función renal: Grupo A (> –3,52 ml/min/1,73 m2) y 52 pacientes tuvieron una progresión lenta de la insuficiencia renal: Grupo B (< –3,2 ml/min/1,73 m2). Por regresión de Cox, en un modelo ajustado, la PAS y la menor edad al diagnóstico son las variables que mantienen su poder predictivo de mal pronóstico renal (p = 0,026). Conclusiones: La función renal inicial, proteinuria, tamaño renal, hipercolesterolemia, hiperuricemia y PAS basal son factores que influyen en la progresión de la insuficiencia renal en la PQRAD, siendo la PAS y la menor edad los factores que mantienen su poder  predictivo independiente en el análisis multivariante." ] "en" => array:1 [ "resumen" => "Objectives: The aim of this study was to analyse the factors influencing chronic kidney disease (CKD) progression in patients with autosomal dominant polycystic kidney disease (ADPKD). Material and Method: We studied 101 patients (mean age: 43±17.3 years, 43.56% male) followed during a median (interquartile range) follow-up time of 69 (35-128) months from 1997 to 2010. The primary end point was: time to a 50% decrease of estimated glomerular filtration rate (eGFR) (CKD-EPI) since the first-time visit and/or time to initiation of renal replacement therapy, and the annual mean change of eGFR was also analysed. Clinical and demographic data, blood pressure, concomitant medications, and analytical parameters were collected at each visit. Baseline kidney size was also recorded by ultrasound. Results: Thirty-one patients achieved the primary end point after a median (IQR) time of 102 (53-131) months. Those patients who achieved the primary end point had higher SBP and DBP (P=0.017 and P=0.001), higher LDL-cholesterol (P=0.011), higher creatinine (P=0.006), higher uricemia (P=0.041), more severe proteinuria (P=0.033) and greater kidney size (P=0.05). The mean annual eGFR change was of –3.52±7.3ml/min/1.73m2. Forty-nine patients had a rapid decline in renal function: Group A (higher than -3.52ml/min/1.73m2) and 52 patients had a lower renal disease progression: Group B (<–3.2 ml/min/1.73 m2). Adjusted Cox regression analysis showed that higher SBP and younger age at the first visit were independent variables for poorer renal outcome (P=0.026). Conclusions: Initial kidney function, proteinuria, renal size, hypercholesterolemia, hyperuricemia, and SBP are the factors that influence CKD progression in ADPKD. SBP and younger age at diagnosis are the only factors that maintain their independent predictive value in a multivariant analysis." ] ] "multimedia" => array:7 [ 0 => array:8 [ "identificador" => "fig1" "etiqueta" => "Tab. 1" "tipo" => "MULTIMEDIAFIGURA" "mostrarFloat" => true "mostrarDisplay" => false "copyright" => "Elsevier España" "figura" => array:1 [ 0 => array:4 [ "imagen" => "11177_16025_26764_en_t1_11177.jpg" "Alto" => 477 "Ancho" => 1063 "Tamanyo" => 744603 ] ] "descripcion" => array:1 [ "en" => "Baseline patient characteristics (qualitative variables)" ] ] 1 => array:8 [ "identificador" => "fig2" "etiqueta" => "Tab. 2" "tipo" => "MULTIMEDIAFIGURA" "mostrarFloat" => true "mostrarDisplay" => false "copyright" => "Elsevier España" "figura" => array:1 [ 0 => array:4 [ "imagen" => "11177_16025_26765_en_t2_11177.jpg" "Alto" => 1266 "Ancho" => 1054 "Tamanyo" => 1112817 ] ] "descripcion" => array:1 [ "en" => "Baseline patient characteristics (quantitative variables)" ] ] 2 => array:8 [ "identificador" => "fig3" "etiqueta" => "Tab. 3" "tipo" => "MULTIMEDIAFIGURA" "mostrarFloat" => true "mostrarDisplay" => false "copyright" => "Elsevier España" "figura" => array:1 [ 0 => array:4 [ "imagen" => "11177_16025_26766_en_t3_11177.jpg" "Alto" => 617 "Ancho" => 2170 "Tamanyo" => 982331 ] ] "descripcion" => array:1 [ "en" => "Predictive factors for renal events. Univariate analysis" ] ] 3 => array:8 [ "identificador" => "fig4" "etiqueta" => "Tab. 4" "tipo" => "MULTIMEDIAFIGURA" "mostrarFloat" => true "mostrarDisplay" => false "copyright" => "Elsevier España" "figura" => array:1 [ 0 => array:4 [ "imagen" => "11177_16025_26768_en_t4_11177.jpg" "Alto" => 273 "Ancho" => 2164 "Tamanyo" => 768300 ] ] "descripcion" => array:1 [ "en" => "Predictive factors for a rapid progression in kidney disease. Univariate analysis (Student’s t-test)" ] ] 4 => array:8 [ "identificador" => "fig5" "etiqueta" => "Tab. 5" "tipo" => "MULTIMEDIAFIGURA" "mostrarFloat" => true "mostrarDisplay" => false "copyright" => "Elsevier España" "figura" => array:1 [ 0 => array:4 [ "imagen" => "11177_16025_26769_en_t5_11177.jpg" "Alto" => 210 "Ancho" => 2157 "Tamanyo" => 693428 ] ] "descripcion" => array:1 [ "en" => "Predictive variables for a rapid progression in kidney disease. Logistic regression" ] ] 5 => array:8 [ "identificador" => "fig6" "etiqueta" => "Fig. 1" "tipo" => "MULTIMEDIAFIGURA" "mostrarFloat" => true "mostrarDisplay" => false "copyright" => "Elsevier España" "figura" => array:1 [ 0 => array:4 [ "imagen" => "11177_16025_26770_en_f1_11177.jpg" "Alto" => 964 "Ancho" => 1880 "Tamanyo" => 1453405 ] ] "descripcion" => array:1 [ "en" => "Decrease in glomerular filtration rate in all patients and in the two different groups of disease progression" ] ] 6 => array:8 [ "identificador" => "fig7" "etiqueta" => "Fig. 2" "tipo" => "MULTIMEDIAFIGURA" "mostrarFloat" => true "mostrarDisplay" => false "copyright" => "Elsevier España" "figura" => array:1 [ 0 => array:4 [ "imagen" => "11177_16025_26771_en_f2__11177.jpg" "Alto" => 944 "Ancho" => 1013 "Tamanyo" => 1024798 ] ] "descripcion" => array:1 [ "en" => "Evolution over time of SBP and DBP values during follow-up. Mean (SD)" ] ] ] "bibliografia" => array:2 [ "titulo" => "Bibliography" "seccion" => array:1 [ 0 => array:1 [ "bibliografiaReferencia" => array:51 [ 0 => array:3 [ "identificador" => "bib1" "etiqueta" => "1" "referencia" => array:1 [ 0 => array:3 [ "referenciaCompleta" => "Schrier RW, McFann KK, Johnson AM. Epidemiological study of kidney survival in autosomal dominant polycystic kidney disease., Kidney Int 2003;63(2):678-85. <a href="http://www.ncbi.nlm.nih.gov/pubmed/12631134" target="_blank">[Pubmed]</a>" "contribucion" => array:1 [ 0 => null ] "host" => array:1 [ 0 => null ] ] ] ] 1 => array:3 [ "identificador" => "bib2" "etiqueta" => "2" "referencia" => array:1 [ 0 => array:3 [ "referenciaCompleta" => "Igarashi P, Somlo S. Polycystic kidney disease. J Am Soc Nephrol 2007;18(5):1371-3. <a href="http://www.ncbi.nlm.nih.gov/pubmed/17429047" target="_blank">[Pubmed]</a>" "contribucion" => array:1 [ 0 => null ] "host" => array:1 [ 0 => null ] ] ] ] 2 => array:3 [ "identificador" => "bib3" "etiqueta" => "3" "referencia" => array:1 [ 0 => array:3 [ "referenciaCompleta" => "Cadnapaphornchai MA, George DM, Masoumi A, McFann K, Strain JD,\u{A0}Schrier RW. Effect of statin therapy on disease progression in pediatric ADPKD: design and baseline characteristics of participants. Contemp Clin Trials 2011;32(3):437-45. <a href="http://www.ncbi.nlm.nih.gov/pubmed/21266204" target="_blank">[Pubmed]</a>" "contribucion" => array:1 [ 0 => null ] "host" => array:1 [ 0 => null ] ] ] ] 3 => array:3 [ "identificador" => "bib4" "etiqueta" => "4" "referencia" => array:1 [ 0 => array:3 [ "referenciaCompleta" => "Bleyer AJ,\u{A0}Hart TC. Polycystic kidney disease. N Engl J Med 2004;350(25):2622. <a href="http://www.ncbi.nlm.nih.gov/pubmed/15201424" target="_blank">[Pubmed]</a>" "contribucion" => array:1 [ 0 => null ] "host" => array:1 [ 0 => null ] ] ] ] 4 => array:3 [ "identificador" => "bib5" "etiqueta" => "5" "referencia" => array:1 [ 0 => array:3 [ "referenciaCompleta" => "Torres VE, Grantham JJ, Chapman AB, Mrug M, Bae KT, King BF, et al. Potentially modifiable factors affecting the progression of autosomal dominant polycystic kidney disease. Clin J Am Soc Nephrol 2011;6(3):640-7. <a href="http://www.ncbi.nlm.nih.gov/pubmed/21088290" target="_blank">[Pubmed]</a>" "contribucion" => array:1 [ 0 => null ] "host" => array:1 [ 0 => null ] ] ] ] 5 => array:3 [ "identificador" => "bib6" "etiqueta" => "6" "referencia" => array:1 [ 0 => array:3 [ "referenciaCompleta" => "Meijer E, Rook M, Tent H, Navis G, van der Jagt EJ, de Jong P, et al. Early renal abnormalities in autosomal dominant polycystic kidney disease. Clin J Am Soc Nephrol 2010;5(6):1091-8. <a href="http://www.ncbi.nlm.nih.gov/pubmed/20413443" target="_blank">[Pubmed]</a>" "contribucion" => array:1 [ 0 => null ] "host" => array:1 [ 0 => null ] ] ] ] 6 => array:3 [ "identificador" => "bib7" "etiqueta" => "7" "referencia" => array:1 [ 0 => array:3 [ "referenciaCompleta" => "Reiterova J, Obeidova H, Lenicek M, Stekrova J, Merta M, Maixnerova D, et al. Influence of VEGF polymorphism on progression of autosomal dominant polycystic kidney disease. Kidney Blood Press Res 2008;31(6):398-403. <a href="http://www.ncbi.nlm.nih.gov/pubmed/19060482" target="_blank">[Pubmed]</a>" "contribucion" => array:1 [ 0 => null ] "host" => array:1 [ 0 => null ] ] ] ] 7 => array:3 [ "identificador" => "bib8" "etiqueta" => "8" "referencia" => array:1 [ 0 => array:3 [ "referenciaCompleta" => "Torres VE, Meijer E, Bae KT, Chapman AB, Devuyst O, Gansevoort RT, et al. Rationale and design of the TEMPO (Tolvaptan Efficacy and Safety in Management of Autosomal Dominant Polycystic Kidney Disease and its Outcomes) 3-4 Study. Am J Kidney Dis 2011;57(5):692-9. <a href="http://www.ncbi.nlm.nih.gov/pubmed/21333426" target="_blank">[Pubmed]</a>" "contribucion" => array:1 [ 0 => null ] "host" => array:1 [ 0 => null ] ] ] ] 8 => array:3 [ "identificador" => "bib9" "etiqueta" => "9" "referencia" => array:1 [ 0 => array:3 [ "referenciaCompleta" => "Irazabal MV, Torres VE, Hogan MC, Glockner J, King BF, Ofstie TG, et al. Short-term effects of tolvaptan on renal function and volume in patients with autosomal dominant polycystic kidney disease. Kidney Int 2011;80(3):295-301. <a href="http://www.ncbi.nlm.nih.gov/pubmed/21544064" target="_blank">[Pubmed]</a>" "contribucion" => array:1 [ 0 => null ] "host" => array:1 [ 0 => null ] ] ] ] 9 => array:3 [ "identificador" => "bib10" "etiqueta" => "10" "referencia" => array:1 [ 0 => array:3 [ "referenciaCompleta" => "Grantham JJ, Bennett WM,\u{A0}Perrone RD. mTOR inhibitors and autosomal dominant polycystic kidney disease. N Engl J Med 2011;364(3):286-7.\u{A0}Author reply 287-9." "contribucion" => array:1 [ 0 => null ] "host" => array:1 [ 0 => null ] ] ] ] 10 => array:3 [ "identificador" => "bib11" "etiqueta" => "11" "referencia" => array:1 [ 0 => array:3 [ "referenciaCompleta" => "11 Ruggenenti P, Remuzzi A, Ondei P, Fasolini G, Antiga L, Ene-Iordache B, et al. Safety and efficacy of long-acting somatostatin treatment in autosomal-dominant polycystic kidney disease. Kidney Int 2005;68(1):206-16. <a href="http://www.ncbi.nlm.nih.gov/pubmed/15954910" target="_blank">[Pubmed]</a>" "contribucion" => array:1 [ 0 => null ] "host" => array:1 [ 0 => null ] ] ] ] 11 => array:3 [ "identificador" => "bib12" "etiqueta" => "12" "referencia" => array:1 [ 0 => array:3 [ "referenciaCompleta" => "Dai B, Liu Y, Mei C, Fu L, Xiong X, Zhang Y, et al. Rosiglitazone attenuates development of polycystic kidney disease and prolongs survival in Han: SPRD rats. Clin Sci (Lond) 2010;119(8):323-33." "contribucion" => array:1 [ 0 => null ] "host" => array:1 [ 0 => null ] ] ] ] 12 => array:3 [ "identificador" => "bib13" "etiqueta" => "13" "referencia" => array:1 [ 0 => array:3 [ "referenciaCompleta" => "Schrier RW. Hypertension and autosomal dominant polycystic kidney disease. Am J Kidney Dis 2011;57(6):811-3. <a href="http://www.ncbi.nlm.nih.gov/pubmed/21601126" target="_blank">[Pubmed]</a>" "contribucion" => array:1 [ 0 => null ] "host" => array:1 [ 0 => null ] ] ] ] 13 => array:3 [ "identificador" => "bib14" "etiqueta" => "14" "referencia" => array:1 [ 0 => array:3 [ "referenciaCompleta" => "Schrier RW, Johnson AM, McFann K,\u{A0}Chapman AB. The role of parental hypertension in the frequency and age of diagnosis of hypertension in offspring with autosomal-dominant polycystic kidney disease. Kidney Int 2003;64(5):1792-9. <a href="http://www.ncbi.nlm.nih.gov/pubmed/14531813" target="_blank">[Pubmed]</a>" "contribucion" => array:1 [ 0 => null ] "host" => array:1 [ 0 => null ] ] ] ] 14 => array:3 [ "identificador" => "bib15" "etiqueta" => "15" "referencia" => array:1 [ 0 => array:3 [ "referenciaCompleta" => "Yium J, Gabow P, Johnson A, Kimberling W, Martinez-Maldonado M. Autosomal dominant polycystic kidney disease in blacks: clinical course and effects of sickle-cell hemoglobin. J Am Soc Nephrol 1994;4(9):1670-4. <a href="http://www.ncbi.nlm.nih.gov/pubmed/8011976" target="_blank">[Pubmed]</a>" "contribucion" => array:1 [ 0 => null ] "host" => array:1 [ 0 => null ] ] ] ] 15 => array:3 [ "identificador" => "bib16" "etiqueta" => "16" "referencia" => array:1 [ 0 => array:3 [ "referenciaCompleta" => "Belibi FA,\u{A0}Edelstein CL. Unified ultrasonographic diagnostic criteria for polycystic kidney disease. J Am Soc Nephrol 2009;20(1):6-8. <a href="http://www.ncbi.nlm.nih.gov/pubmed/19073819" target="_blank">[Pubmed]</a>" "contribucion" => array:1 [ 0 => null ] "host" => array:1 [ 0 => null ] ] ] ] 16 => array:3 [ "identificador" => "bib17" "etiqueta" => "17" "referencia" => array:1 [ 0 => array:3 [ "referenciaCompleta" => "Grossfeld GD, Wolf JS Jr, Litwan MS, Hricak H, Shuler CL, Agerter DC, et al. Asymptomatic microscopic hematuria in adults: summary of the AUA best practice policy recommendations. Am Fam Physician 2001;63(6):1145-54. <a href="http://www.ncbi.nlm.nih.gov/pubmed/11277551" target="_blank">[Pubmed]</a>" "contribucion" => array:1 [ 0 => null ] "host" => array:1 [ 0 => null ] ] ] ] 17 => array:3 [ "identificador" => "bib18" "etiqueta" => "18" "referencia" => array:1 [ 0 => array:3 [ "referenciaCompleta" => "Marín R, de la Sierra A, Armario P, Campo C, Banegas JR, Gorostidi M. 2005 Spanish guidelines in diagnosis and treatment of arterial hypertension. Med Clin (Barc) 2005;125(1):24-34." "contribucion" => array:1 [ 0 => null ] "host" => array:1 [ 0 => null ] ] ] ] 18 => array:3 [ "identificador" => "bib19" "etiqueta" => "19" "referencia" => array:1 [ 0 => array:3 [ "referenciaCompleta" => "Jones DW,\u{A0}Hall JE. Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure and evidence from new hypertension trials. Hypertension 2004;43(1):1-3. <a href="http://www.ncbi.nlm.nih.gov/pubmed/14676222" target="_blank">[Pubmed]</a>" "contribucion" => array:1 [ 0 => null ] "host" => array:1 [ 0 => null ] ] ] ] 19 => array:3 [ "identificador" => "bib20" "etiqueta" => "20" "referencia" => array:1 [ 0 => array:3 [ "referenciaCompleta" => "Lobos JM, Royo-Bordonada MA, Brotons C, Álvarez-Sala L, Armario P, Maiques A,\u{A0}et al. European Guidelines on Cardiovascular Disease Prevention in Clinical Practice. CEIPC 2008 Spanish adaptation. Rev Clin Esp 2009;209(6):279-302. <a href="http://www.ncbi.nlm.nih.gov/pubmed/19635253" target="_blank">[Pubmed]</a>" "contribucion" => array:1 [ 0 => null ] "host" => array:1 [ 0 => null ] ] ] ] 20 => array:3 [ "identificador" => "bib21" "etiqueta" => "21" "referencia" => array:1 [ 0 => array:3 [ "referenciaCompleta" => "Levey AS, Stevens LA, Schmid CH, Zhang YL, Castro AF 3rd, Feldman HI, et al. A new equation to estimate glomerular filtration rate. Ann Intern Med 2009;150(9):604-12. <a href="http://www.ncbi.nlm.nih.gov/pubmed/19414839" target="_blank">[Pubmed]</a>" "contribucion" => array:1 [ 0 => null ] "host" => array:1 [ 0 => null ] ] ] ] 21 => array:3 [ "identificador" => "bib22" "etiqueta" => "22" "referencia" => array:1 [ 0 => array:3 [ "referenciaCompleta" => "Tokiwa S, Muto S, China T,\u{A0}Horie S. The relationship between renal volume and renal function in autosomal dominant polycystic kidney disease. Clin Exp Nephrol 2011;15(4):539-45. <a href="http://www.ncbi.nlm.nih.gov/pubmed/21431900" target="_blank">[Pubmed]</a>" "contribucion" => array:1 [ 0 => null ] "host" => array:1 [ 0 => null ] ] ] ] 22 => array:3 [ "identificador" => "bib23" "etiqueta" => "23" "referencia" => array:1 [ 0 => array:3 [ "referenciaCompleta" => "Dicks E, Ravani P, Langman D, Davidson WS, Pei Y,\u{A0}Parfrey PS. Incident renal events and risk factors in autosomal dominant polycystic kidney disease: a population and family-based cohort followed for 22 years. Clin J Am Soc Nephrol 2006;1(4):710-7. <a href="http://www.ncbi.nlm.nih.gov/pubmed/17699277" target="_blank">[Pubmed]</a>" "contribucion" => array:1 [ 0 => null ] "host" => array:1 [ 0 => null ] ] ] ] 23 => array:3 [ "identificador" => "bib24" "etiqueta" => "24" "referencia" => array:1 [ 0 => array:3 [ "referenciaCompleta" => "Chapman AB. Approaches to testing new treatments in autosomal dominant polycystic kidney disease: insights from the CRISP and HALT-PKD studies. Clin J Am Soc Nephrol 2008;3(4):1197-204. <a href="http://www.ncbi.nlm.nih.gov/pubmed/18579674" target="_blank">[Pubmed]</a>" "contribucion" => array:1 [ 0 => null ] "host" => array:1 [ 0 => null ] ] ] ] 24 => array:3 [ "identificador" => "bib25" "etiqueta" => "25" "referencia" => array:1 [ 0 => array:3 [ "referenciaCompleta" => "Chapman AB, Guay-Woodford LM, Grantham JJ, Torres VE, Bae KT, Baumgarten DA, et al. Renal structure in early autosomal-dominant polycystic kidney disease (ADPKD): The Consortium for Radiologic Imaging Studies of Polycystic Kidney Disease (CRISP) cohort. Kidney Int 2003;64(3):1035-45. <a href="http://www.ncbi.nlm.nih.gov/pubmed/12911554" target="_blank">[Pubmed]</a>" "contribucion" => array:1 [ 0 => null ] "host" => array:1 [ 0 => null ] ] ] ] 25 => array:3 [ "identificador" => "bib26" "etiqueta" => "26" "referencia" => array:1 [ 0 => array:3 [ "referenciaCompleta" => "King BF, Reed JE, Bergstralh EJ, Sheedy PF, Torres VE. Quantification and longitudinal trends of kidney, renal cysts and renal parenchyma volumes in Autosomal dominant polycystic kidney disease. J Am Soc Nephrol 2000;11(8):1505-11. <a href="http://www.ncbi.nlm.nih.gov/pubmed/10906164" target="_blank">[Pubmed]</a>" "contribucion" => array:1 [ 0 => null ] "host" => array:1 [ 0 => null ] ] ] ] 26 => array:3 [ "identificador" => "bib27" "etiqueta" => "27" "referencia" => array:1 [ 0 => array:3 [ "referenciaCompleta" => "Chapman, AB,\u{A0}Wei W. Imaging approaches to patients with polycystic kidney disease. Semin Nephrol 2011;31(3):237-44. <a href="http://www.ncbi.nlm.nih.gov/pubmed/21784272" target="_blank">[Pubmed]</a>" "contribucion" => array:1 [ 0 => null ] "host" => array:1 [ 0 => null ] ] ] ] 27 => array:3 [ "identificador" => "bib28" "etiqueta" => "28" "referencia" => array:1 [ 0 => array:3 [ "referenciaCompleta" => "Antiga L, Piccinelli M, Fasolini G, Ene-Iordache B, Ondei P, Bruno S, et al. Computed tomography evaluation of autosomal dominant polycystic kidney disease progression: a progress report. Clin J Am Soc Nephrol 2006;1(4):754-60. <a href="http://www.ncbi.nlm.nih.gov/pubmed/17699283" target="_blank">[Pubmed]</a>" "contribucion" => array:1 [ 0 => null ] "host" => array:1 [ 0 => null ] ] ] ] 28 => array:3 [ "identificador" => "bib29" "etiqueta" => "29" "referencia" => array:1 [ 0 => array:3 [ "referenciaCompleta" => "Kazancioglu R, Ecder T, Altintepe L, Altiparmak MR, Tuglular S, Uyanik A, et al. Demographic and clinical characteristics of patients with autosomal dominant polycystic kidney disease: a multicenter experience. Nephron Clin Pract 2011;117(3):c270-5. <a href="http://www.ncbi.nlm.nih.gov/pubmed/20847569" target="_blank">[Pubmed]</a>" "contribucion" => array:1 [ 0 => null ] "host" => array:1 [ 0 => null ] ] ] ] 29 => array:3 [ "identificador" => "bib30" "etiqueta" => "30" "referencia" => array:1 [ 0 => array:3 [ "referenciaCompleta" => "Ecder T, Schrier RW. Hypertension in autosomal-dominant polycystic kidney disease: early occurrence and unique aspects. J Am Soc Nephrol 2001;12(1):194-200. <a href="http://www.ncbi.nlm.nih.gov/pubmed/11134267" target="_blank">[Pubmed]</a>" "contribucion" => array:1 [ 0 => null ] "host" => array:1 [ 0 => null ] ] ] ] 30 => array:3 [ "identificador" => "bib31" "etiqueta" => "31" "referencia" => array:1 [ 0 => array:3 [ "referenciaCompleta" => "Ahmed ER, Tashkandi MA, Nahrir S, Maulana A. Retrospective analysis of factors affecting the progression of chronic renal failure in adult polycystic kidney disease. Saudi J Kidney Dis Transpl 2006;17(4):511-5. <a href="http://www.ncbi.nlm.nih.gov/pubmed/17186685" target="_blank">[Pubmed]</a>" "contribucion" => array:1 [ 0 => null ] "host" => array:1 [ 0 => null ] ] ] ] 31 => array:3 [ "identificador" => "bib32" "etiqueta" => "32" "referencia" => array:1 [ 0 => array:3 [ "referenciaCompleta" => "Idrizi A, Barbullushi M, Strakosha A, Kodra S, Thereska N, Zaimi E, et al. The relation of hypertension, renal function and cardiovascular events in autosomal dominant polycystic kidney disease. G Ital Nefrol 2007;24(6):595-9. <a href="http://www.ncbi.nlm.nih.gov/pubmed/18278763" target="_blank">[Pubmed]</a>" "contribucion" => array:1 [ 0 => null ] "host" => array:1 [ 0 => null ] ] ] ] 32 => array:3 [ "identificador" => "bib33" "etiqueta" => "33" "referencia" => array:1 [ 0 => array:3 [ "referenciaCompleta" => "Patch C, Charlton J, Roderick PJ,\u{A0}Gulliford MC. Use of antihypertensive medications and mortality of patients with autosomal dominant polycystic kidney disease: a population-based study. Am J Kidney Dis 2011;57(6):856-62. <a href="http://www.ncbi.nlm.nih.gov/pubmed/21458899" target="_blank">[Pubmed]</a>" "contribucion" => array:1 [ 0 => null ] "host" => array:1 [ 0 => null ] ] ] ] 33 => array:3 [ "identificador" => "bib34" "etiqueta" => "34" "referencia" => array:1 [ 0 => array:3 [ "referenciaCompleta" => "Orskov B, Romming Sorensen V, Feldt-Rasmussen B,\u{A0}Strandgaard S. Improved prognosis in patients with autosomal dominant polycystic kidney disease in Denmark. Clin J Am Soc Nephrol 2010;5(11):2034-9. <a href="http://www.ncbi.nlm.nih.gov/pubmed/20671227" target="_blank">[Pubmed]</a>" "contribucion" => array:1 [ 0 => null ] "host" => array:1 [ 0 => null ] ] ] ] 34 => array:3 [ "identificador" => "bib35" "etiqueta" => "35" "referencia" => array:1 [ 0 => array:3 [ "referenciaCompleta" => "Nakamura T, Sato E, Fujiwara N, Kawagoe Y, Yamada S, Ueda Y, et al. Changes in Urinary Albumin Excretion, Inflammatory and Oxidative Stress Markers in ADPKD Patients with Hypertension. Am J Med Sci 2012;343(1):46-51. <a href="http://www.ncbi.nlm.nih.gov/pubmed/21760473" target="_blank">[Pubmed]</a>" "contribucion" => array:1 [ 0 => null ] "host" => array:1 [ 0 => null ] ] ] ] 35 => array:3 [ "identificador" => "bib36" "etiqueta" => "36" "referencia" => array:1 [ 0 => array:3 [ "referenciaCompleta" => "Sans L, Roca-Cuchars A, Torra R, Calero F, Arias P, Ballarin J, et al. Relationship between kidney size and blood pressure profile in patients with Autosomal dominant polycystic kidney disease without renal failure. Nefrologia 2010;30(5):567-72. <a href="http://www.ncbi.nlm.nih.gov/pubmed/20882096" target="_blank">[Pubmed]</a>" "contribucion" => array:1 [ 0 => null ] "host" => array:1 [ 0 => null ] ] ] ] 36 => array:3 [ "identificador" => "bib37" "etiqueta" => "37" "referencia" => array:1 [ 0 => array:3 [ "referenciaCompleta" => "Cadnapaphornchai MA, McFann K, Strain JD, Masoumi A, Schrier RW. Increased left\u{A0}ventricular mass in children with Autosomal dominant polycystic kidney disease and borderline\u{A0}hypertension. Kidney Int 2008;74(9):1192-6. <a href="http://www.ncbi.nlm.nih.gov/pubmed/18716604" target="_blank">[Pubmed]</a>" "contribucion" => array:1 [ 0 => null ] "host" => array:1 [ 0 => null ] ] ] ] 37 => array:3 [ "identificador" => "bib38" "etiqueta" => "38" "referencia" => array:1 [ 0 => array:3 [ "referenciaCompleta" => "Agarwal R. Blood pressure components and the risk for end-stage renal disease and death in chronic kidney disease. Clin J Am Soc Nephrol 2009;4(4):830-7. <a href="http://www.ncbi.nlm.nih.gov/pubmed/19339424" target="_blank">[Pubmed]</a>" "contribucion" => array:1 [ 0 => null ] "host" => array:1 [ 0 => null ] ] ] ] 38 => array:3 [ "identificador" => "bib39" "etiqueta" => "39" "referencia" => array:1 [ 0 => array:3 [ "referenciaCompleta" => "Wuhl E, Schaefer F. Managing kidney disease with blood-pressure control. Nat Rev Nephrol 2011;7(8):434-44. <a href="http://www.ncbi.nlm.nih.gov/pubmed/21691318" target="_blank">[Pubmed]</a>" "contribucion" => array:1 [ 0 => null ] "host" => array:1 [ 0 => null ] ] ] ] 39 => array:3 [ "identificador" => "bib40" "etiqueta" => "40" "referencia" => array:1 [ 0 => array:3 [ "referenciaCompleta" => "Wenzel RR. Renal protection in hypertensive patients: selection of antihypertensive therapy. Drugs 2005;65 Suppl 2:29-39. <a href="http://www.ncbi.nlm.nih.gov/pubmed/16398060" target="_blank">[Pubmed]</a>" "contribucion" => array:1 [ 0 => null ] "host" => array:1 [ 0 => null ] ] ] ] 40 => array:3 [ "identificador" => "bib41" "etiqueta" => "41" "referencia" => array:1 [ 0 => array:3 [ "referenciaCompleta" => "Chapman AB, Torres VE, Perrone RD, Steinman TI, Bae KT, Miller JP, et al. The HALT polycystic kidney disease trials: design and implementation. Clin J Am Soc Nephrol 2010;5(1):102-9. <a href="http://www.ncbi.nlm.nih.gov/pubmed/20089507" target="_blank">[Pubmed]</a>" "contribucion" => array:1 [ 0 => null ] "host" => array:1 [ 0 => null ] ] ] ] 41 => array:3 [ "identificador" => "bib42" "etiqueta" => "42" "referencia" => array:1 [ 0 => array:3 [ "referenciaCompleta" => "Sarnak MJ,\u{A0}Astor BC. Implications of Proteinuria: CKD progression and cardiovascular outcomes. Adv Chronic Kidney Dis 2011;18(4):258-66. <a href="http://www.ncbi.nlm.nih.gov/pubmed/21782132" target="_blank">[Pubmed]</a>" "contribucion" => array:1 [ 0 => null ] "host" => array:1 [ 0 => null ] ] ] ] 42 => array:3 [ "identificador" => "bib43" "etiqueta" => "43" "referencia" => array:1 [ 0 => array:3 [ "referenciaCompleta" => "Hateboer N, van Dijk MA, Bogdanova N, Coto E, Saggar-Malik AK, San Millan JL, et al. Comparison of phenotypes of polycystic kidney disease types 1 and 2. European PKD1-PKD2 Study Group. Lancet 1999;353(9147):103-7." "contribucion" => array:1 [ 0 => null ] "host" => array:1 [ 0 => null ] ] ] ] 43 => array:3 [ "identificador" => "bib44" "etiqueta" => "44" "referencia" => array:1 [ 0 => array:3 [ "referenciaCompleta" => "Grantham JJ. Clinical practice. Autosomal dominant polycystic kidney disease. N Engl J Med 2008;359(14):1477-85. <a href="http://www.ncbi.nlm.nih.gov/pubmed/18832246" target="_blank">[Pubmed]</a>" "contribucion" => array:1 [ 0 => null ] "host" => array:1 [ 0 => null ] ] ] ] 44 => array:3 [ "identificador" => "bib45" "etiqueta" => "45" "referencia" => array:1 [ 0 => array:3 [ "referenciaCompleta" => "Torra R, Badenas C, Pérez-Oller L, Luis J, Millán S, Nicolau C. Increased prevalence of polycystic kidney disease type 2 among elderly polycystic patients. Am J Kidney Dis 2000;36(4):728-34. <a href="http://www.ncbi.nlm.nih.gov/pubmed/11007674" target="_blank">[Pubmed]</a>" "contribucion" => array:1 [ 0 => null ] "host" => array:1 [ 0 => null ] ] ] ] 45 => array:3 [ "identificador" => "bib46" "etiqueta" => "46" "referencia" => array:1 [ 0 => array:3 [ "referenciaCompleta" => "Barua M, Cil O, Paterson AD, Wang K, He N, Dicks E, et al. Family history of renal disease severity predicts the mutated gene in ADPKD. J Am Soc Nephrol 2009;20(8):1833-8. <a href="http://www.ncbi.nlm.nih.gov/pubmed/19443633" target="_blank">[Pubmed]</a>" "contribucion" => array:1 [ 0 => null ] "host" => array:1 [ 0 => null ] ] ] ] 46 => array:3 [ "identificador" => "bib47" "etiqueta" => "47" "referencia" => array:1 [ 0 => array:3 [ "referenciaCompleta" => "Hosoya T, Ichida K, Tabe A,\u{A0}Sakai O. A study of uric acid metabolism and gouty arthritis in patients with polycystic kidney. Nippon Jinzo Gakkai Shi 1993;35(1):43-8. <a href="http://www.ncbi.nlm.nih.gov/pubmed/8336399" target="_blank">[Pubmed]</a>" "contribucion" => array:1 [ 0 => null ] "host" => array:1 [ 0 => null ] ] ] ] 47 => array:3 [ "identificador" => "bib48" "etiqueta" => "48" "referencia" => array:1 [ 0 => array:3 [ "referenciaCompleta" => "Kuo CF, Luo SF, See LC, Ko YS, Chen YM, Hwang JS, et al. Hyperuricaemia and accelerated reduction in renal function. Scand J Rheumatol 2011;40(2):116-21. <a href="http://www.ncbi.nlm.nih.gov/pubmed/20868309" target="_blank">[Pubmed]</a>" "contribucion" => array:1 [ 0 => null ] "host" => array:1 [ 0 => null ] ] ] ] 48 => array:3 [ "identificador" => "bib49" "etiqueta" => "49" "referencia" => array:1 [ 0 => array:3 [ "referenciaCompleta" => "Feig DI. Uric acid: a novel mediator and marker of risk in chronic kidney disease? Curr Opin Nephrol Hypertens 2009;18(6):526-30. <a href="http://www.ncbi.nlm.nih.gov/pubmed/19654543" target="_blank">[Pubmed]</a>" "contribucion" => array:1 [ 0 => null ] "host" => array:1 [ 0 => null ] ] ] ] 49 => array:3 [ "identificador" => "bib50" "etiqueta" => "50" "referencia" => array:1 [ 0 => array:3 [ "referenciaCompleta" => "Goicoechea M, de Vinuesa SG, Verdalles U, Ruiz-Caro C, Ampuero J, Rincon A, et al. Effect of allopurinol in chronic kidney disease progression and cardiovascular risk. Clin J Am Soc Nephrol 2010;5(8):1388-93. <a href="http://www.ncbi.nlm.nih.gov/pubmed/20538833" target="_blank">[Pubmed]</a>" "contribucion" => array:1 [ 0 => null ] "host" => array:1 [ 0 => null ] ] ] ] 50 => array:3 [ "identificador" => "bib51" "etiqueta" => "51" "referencia" => array:1 [ 0 => array:3 [ "referenciaCompleta" => "van Dijk MA, Kamper AM, van Veen S, Souverijn JH,\u{A0}Blauw GJ. Effect of simvastatin on renal function in autosomal dominant polycystic kidney disease. Nephrol Dial Transplant 2001;16(11):2152-7. <a href="http://www.ncbi.nlm.nih.gov/pubmed/11682660" target="_blank">[Pubmed]</a>" "contribucion" => array:1 [ 0 => null ] "host" => array:1 [ 0 => null ] ] ] ] ] ] ] ] ] "idiomaDefecto" => "en" "url" => "/20132514/0000003200000002/v0_201502091616/X2013251412000914/v0_201502091617/en/main.assets" "Apartado" => array:4 [ "identificador" => "35441" "tipo" => "SECCION" "en" => array:2 [ "titulo" => "Originals" "idiomaDefecto" => true ] "idiomaDefecto" => "en" ] "PDF" => "https://static.elsevier.es/multimedia/20132514/0000003200000002/v0_201502091616/X2013251412000914/v0_201502091617/en/P1-E534-S3437-A11177-EN.pdf?idApp=UINPBA000064&text.app=https://revistanefrologia.com/" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/X2013251412000914?idApp=UINPBA000064"]

Statistics

Progresión de la enfermedad renal crónica en pacientes con enfermedad poliquística autosómica dominante

Nayara Panizoa, Nayara Panizob, Marian Goicoecheaa, Marian Goicoecheab, Soledad García de Vinuesab, David Arroyoa, David Arroyob, Claudia Yustea, Claudia Yusteb, Abraham Rincóna, Abraham Rincónb, Ursula Verdallesa, Ursula Verdallesb, Caridad Ruiz-Caroc, Borja Quirogab, José Luñob

a Servicio de Nefrología, Hospital General Universitario Gregorio Marañón, Madrid, Spain,

b Servicio de Nefrología, Hospital General Universitario Gregorio Marañón, Madrid,

c Clínica Dialcentro, Madrid,

Read

12015

Times
was read the article

2568

Total PDF

9447

Total HTML

Share statistics

 array:21 [
  "pii" => "X2013251412000914"
  "issn" => "20132514"
  "doi" => "10.3265/Nefrologia.pre2011.Dec.11177"
  "estado" => "S300"
  "fechaPublicacion" => "2012-03-01"
  "documento" => "article"
  "licencia" => "http://www.elsevier.com/open-access/userlicense/1.0/"
  "subdocumento" => "fla"
  "cita" => "Nefrologia &#40;English Version&#41;. 2012;32:197-205"
  "abierto" => array:3 [
    "ES" => true
    "ES2" => true
    "LATM" => true
  ]
  "gratuito" => true
  "lecturas" => array:2 [
    "total" => 7176
    "formatos" => array:3 [
      "EPUB" => 284
      "HTML" => 6160
      "PDF" => 732
    ]
  ]
  "Traduccion" => array:1 [
    "es" => array:17 [
      "pii" => "X0211699512000917"
      "issn" => "02116995"
      "doi" => "10.3265/Nefrologia.pre2011.Dec.11177"
      "estado" => "S300"
      "fechaPublicacion" => "2012-03-01"
      "documento" => "article"
      "licencia" => "http://www.elsevier.com/open-access/userlicense/1.0/"
      "subdocumento" => "fla"
      "cita" => "Nefrologia. 2012;32:197-205"
      "abierto" => array:3 [
        "ES" => true
        "ES2" => true
        "LATM" => true
      ]
      "gratuito" => true
      "lecturas" => array:2 [
        "total" => 10613
        "formatos" => array:3 [
          "EPUB" => 253
          "HTML" => 9745
          "PDF" => 615
        ]
      ]
      "es" => array:12 [
        "idiomaDefecto" => true
        "titulo" => "Progresi&#243;n de la enfermedad renal cr&#243;nica en pacientes con enfermedad poliqu&#237;stica autos&#243;mica dominante"
        "tienePdf" => "es"
        "tieneTextoCompleto" => "es"
        "tieneResumen" => array:2 [
          0 => "es"
          1 => "en"
        ]
        "paginas" => array:1 [
          0 => array:2 [
            "paginaInicial" => "197"
            "paginaFinal" => "205"
          ]
        ]
        "titulosAlternativos" => array:1 [
          "en" => array:1 [
            "titulo" => "Chronic kidney disease progression in patients with autosomal dominant polycystic kidney disease"
          ]
        ]
        "contieneResumen" => array:2 [
          "es" => true
          "en" => true
        ]
        "contieneTextoCompleto" => array:1 [
          "es" => true
        ]
        "contienePdf" => array:1 [
          "es" => true
        ]
        "resumenGrafico" => array:2 [
          "original" => 0
          "multimedia" => array:8 [
            "identificador" => "fig1"
            "etiqueta" => "Tab.  1"
            "tipo" => "MULTIMEDIAFIGURA"
            "mostrarFloat" => true
            "mostrarDisplay" => false
            "copyright" => "Elsevier Espa&#241;a"
            "figura" => array:1 [
              0 => array:4 [
                "imagen" => "11177_108_21581_es_11177_t1.jpg"
                "Alto" => 257
                "Ancho" => 569
                "Tamanyo" => 84616
              ]
            ]
            "descripcion" => array:1 [
              "es" => "Caracter&#237;sticas basales de los pacientes &#40;variables cualitativas&#41;"
            ]
          ]
        ]
        "autores" => array:1 [
          0 => array:2 [
            "autoresLista" => "Nayara Panizo, Marian Goicoechea, Soledad Garc&#237;a de Vinuesa, David Arroyo, Claudia Yuste, Abraham Rinc&#243;n, Ursula Verdalles, Caridad Ruiz-Caro, Borja Quiroga, Jos&#233; Lu&#241;o"
            "autores" => array:16 [
              0 => array:2 [
                "nombre" => "Nayara"
                "apellidos" => "Panizo"
              ]
              1 => array:2 [
                "nombre" => "Nayara"
                "apellidos" => "Panizo"
              ]
              2 => array:2 [
                "nombre" => "Marian"
                "apellidos" => "Goicoechea"
              ]
              3 => array:2 [
                "nombre" => "Marian"
                "apellidos" => "Goicoechea"
              ]
              4 => array:2 [
                "nombre" => "Soledad"
                "apellidos" => "Garc&#237;a de Vinuesa"
              ]
              5 => array:2 [
                "nombre" => "David"
                "apellidos" => "Arroyo"
              ]
              6 => array:2 [
                "nombre" => "David"
                "apellidos" => "Arroyo"
              ]
              7 => array:2 [
                "nombre" => "Claudia"
                "apellidos" => "Yuste"
              ]
              8 => array:2 [
                "nombre" => "Claudia"
                "apellidos" => "Yuste"
              ]
              9 => array:2 [
                "nombre" => "Abraham"
                "apellidos" => "Rinc&#243;n"
              ]
              10 => array:2 [
                "nombre" => "Abraham"
                "apellidos" => "Rinc&#243;n"
              ]
              11 => array:2 [
                "nombre" => "Ursula"
                "apellidos" => "Verdalles"
              ]
              12 => array:2 [
                "nombre" => "Ursula"
                "apellidos" => "Verdalles"
              ]
              13 => array:2 [
                "nombre" => "Caridad"
                "apellidos" => "Ruiz-Caro"
              ]
              14 => array:2 [
                "nombre" => "Borja"
                "apellidos" => "Quiroga"
              ]
              15 => array:2 [
                "nombre" => "Jos&#233;"
                "apellidos" => "Lu&#241;o"
              ]
            ]
          ]
        ]
      ]
      "idiomaDefecto" => "es"
      "Traduccion" => array:1 [
        "en" => array:9 [
          "pii" => "X2013251412000914"
          "doi" => "10.3265/Nefrologia.pre2011.Dec.11177"
          "estado" => "S300"
          "subdocumento" => ""
          "abierto" => array:3 [
            "ES" => true
            "ES2" => true
            "LATM" => true
          ]
          "gratuito" => true
          "lecturas" => array:1 [
            "total" => 0
          ]
          "idiomaDefecto" => "en"
          "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/X2013251412000914?idApp=UINPBA000064"
        ]
      ]
      "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/X0211699512000917?idApp=UINPBA000064"
      "url" => "/02116995/0000003200000002/v0_201502091353/X0211699512000917/v0_201502091353/es/main.assets"
    ]
  ]
  "itemSiguiente" => array:17 [
    "pii" => "X2013251412000906"
    "issn" => "20132514"
    "doi" => "10.3265/Nefrologia.pre2011.Dec.11223"
    "estado" => "S300"
    "fechaPublicacion" => "2012-03-01"
    "documento" => "article"
    "licencia" => "http://www.elsevier.com/open-access/userlicense/1.0/"
    "subdocumento" => "fla"
    "cita" => "Nefrologia &#40;English Version&#41;. 2012;32:206-12"
    "abierto" => array:3 [
      "ES" => true
      "ES2" => true
      "LATM" => true
    ]
    "gratuito" => true
    "lecturas" => array:2 [
      "total" => 11240
      "formatos" => array:3 [
        "EPUB" => 305
        "HTML" => 10038
        "PDF" => 897
      ]
    ]
    "en" => array:12 [
      "idiomaDefecto" => true
      "titulo" => "Congestive heart failure in patients with advanced chronic kidney disease&#58; association with pre-emptive vascular access placement"
      "tienePdf" => "en"
      "tieneTextoCompleto" => "en"
      "tieneResumen" => array:2 [
        0 => "es"
        1 => "en"
      ]
      "paginas" => array:1 [
        0 => array:2 [
          "paginaInicial" => "206"
          "paginaFinal" => "212"
        ]
      ]
      "titulosAlternativos" => array:1 [
        "es" => array:1 [
          "titulo" => "Insuficiencia card&#237;aca en la enfermedad renal cr&#243;nica avanzada&#58; relaci&#243;n con el acceso vascular"
        ]
      ]
      "contieneResumen" => array:2 [
        "es" => true
        "en" => true
      ]
      "contieneTextoCompleto" => array:1 [
        "en" => true
      ]
      "contienePdf" => array:1 [
        "en" => true
      ]
      "resumenGrafico" => array:2 [
        "original" => 0
        "multimedia" => array:8 [
          "identificador" => "fig1"
          "etiqueta" => "Tab.  1"
          "tipo" => "MULTIMEDIAFIGURA"
          "mostrarFloat" => true
          "mostrarDisplay" => false
          "copyright" => "Elsevier Espa&#241;a"
          "figura" => array:1 [
            0 => array:4 [
              "imagen" => "11223_16025_27344_en_t111223en.jpg"
              "Alto" => 1959
              "Ancho" => 2170
              "Tamanyo" => 1348742
            ]
          ]
          "descripcion" => array:1 [
            "en" => "Clinical and laboratory parameters for all patients and each sub-group according to the presence or absence of congestive heart failure"
          ]
        ]
      ]
      "autores" => array:1 [
        0 => array:2 [
          "autoresLista" => "Roc&#237;o Mart&#237;nez Gallardo, Roc&#237;o Mart&#237;nez-Gallardo, Flavio Ferreira Morong, Flavio Ferreira-Morong, Guadalupe Garc&#237;a Pino, Guadalupe Garc&#237;a-Pino, Isis Cerezo Arias, Isis Cerezo-Arias, Rom&#225;n Hern&#225;ndez Gallego, Rom&#225;n Hern&#225;ndez-Gallego, Francisco Caravaca Magari&#241;os"
          "autores" => array:12 [
            0 => array:2 [
              "nombre" => "Roc&#237;o"
              "apellidos" => "Mart&#237;nez Gallardo"
            ]
            1 => array:2 [
              "nombre" => "Roc&#237;o"
              "apellidos" => "Mart&#237;nez-Gallardo"
            ]
            2 => array:2 [
              "nombre" => "Flavio"
              "apellidos" => "Ferreira Morong"
            ]
            3 => array:2 [
              "nombre" => "Flavio"
              "apellidos" => "Ferreira-Morong"
            ]
            4 => array:2 [
              "nombre" => "Guadalupe"
              "apellidos" => "Garc&#237;a Pino"
            ]
            5 => array:2 [
              "nombre" => "Guadalupe"
              "apellidos" => "Garc&#237;a-Pino"
            ]
            6 => array:2 [
              "nombre" => "Isis"
              "apellidos" => "Cerezo Arias"
            ]
            7 => array:2 [
              "nombre" => "Isis"
              "apellidos" => "Cerezo-Arias"
            ]
            8 => array:2 [
              "nombre" => "Rom&#225;n"
              "apellidos" => "Hern&#225;ndez Gallego"
            ]
            9 => array:2 [
              "nombre" => "Rom&#225;n"
              "apellidos" => "Hern&#225;ndez-Gallego"
            ]
            10 => array:2 [
              "nombre" => "Francisco"
              "apellidos" => "Caravaca Magari&#241;os"
            ]
            11 => array:2 [
              "nombre" => "Francisco"
              "apellidos" => "Caravaca"
            ]
          ]
        ]
      ]
    ]
    "idiomaDefecto" => "en"
    "Traduccion" => array:1 [
      "es" => array:9 [
        "pii" => "X0211699512000909"
        "doi" => "10.3265/Nefrologia.pre2011.Dec.11223"
        "estado" => "S300"
        "subdocumento" => ""
        "abierto" => array:3 [
          "ES" => true
          "ES2" => true
          "LATM" => true
        ]
        "gratuito" => true
        "lecturas" => array:1 [
          "total" => 0
        ]
        "idiomaDefecto" => "es"
        "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/X0211699512000909?idApp=UINPBA000064"
      ]
    ]
    "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/X2013251412000906?idApp=UINPBA000064"
    "url" => "/20132514/0000003200000002/v0_201502091616/X2013251412000906/v0_201502091617/en/main.assets"
  ]
  "itemAnterior" => array:17 [
    "pii" => "X2013251412000922"
    "issn" => "20132514"
    "doi" => "10.3265/Nefrologia.pre2011.Nov.10962"
    "estado" => "S300"
    "fechaPublicacion" => "2012-03-01"
    "documento" => "article"
    "licencia" => "http://www.elsevier.com/open-access/userlicense/1.0/"
    "subdocumento" => "fla"
    "cita" => "Nefrologia &#40;English Version&#41;. 2012;32:187-96"
    "abierto" => array:3 [
      "ES" => true
      "ES2" => true
      "LATM" => true
    ]
    "gratuito" => true
    "lecturas" => array:2 [
      "total" => 6713
      "formatos" => array:3 [
        "EPUB" => 276
        "HTML" => 5565
        "PDF" => 872
      ]
    ]
    "en" => array:12 [
      "idiomaDefecto" => true
      "titulo" => "High doses of irbesartan offer long-term kidney protection in cases of established diabetic nephropathy"
      "tienePdf" => "en"
      "tieneTextoCompleto" => "en"
      "tieneResumen" => array:2 [
        0 => "es"
        1 => "en"
      ]
      "paginas" => array:1 [
        0 => array:2 [
          "paginaInicial" => "187"
          "paginaFinal" => "196"
        ]
      ]
      "titulosAlternativos" => array:1 [
        "es" => array:1 [
          "titulo" => "Efectos renoprotectores a largo plazo de dosis altas de irbesart&#225;n en la nefropat&#237;a diab&#233;tica establecida"
        ]
      ]
      "contieneResumen" => array:2 [
        "es" => true
        "en" => true
      ]
      "contieneTextoCompleto" => array:1 [
        "en" => true
      ]
      "contienePdf" => array:1 [
        "en" => true
      ]
      "resumenGrafico" => array:2 [
        "original" => 0
        "multimedia" => array:8 [
          "identificador" => "fig1"
          "etiqueta" => "Tab.  1"
          "tipo" => "MULTIMEDIAFIGURA"
          "mostrarFloat" => true
          "mostrarDisplay" => false
          "copyright" => "Elsevier Espa&#241;a"
          "figura" => array:1 [
            0 => array:4 [
              "imagen" => "10962_16025_27957_en_t1_10962i.jpg"
              "Alto" => 654
              "Ancho" => 1083
              "Tamanyo" => 827943
            ]
          ]
          "descripcion" => array:1 [
            "en" => "Treatments administered over the course of the study period"
          ]
        ]
      ]
      "autores" => array:1 [
        0 => array:2 [
          "autoresLista" => "Silvia Ros Ruiz, Silvia Ros-Ruiz, Pedro Aranda Lara, Pedro Aranda-Lara, Juan Carlos Fern&#225;ndez, Juan C&#46; Fern&#225;ndez, Maria Dolores Mart&#237;nez Esteban, M&#46; Dolores Mart&#237;nez-Esteban, Cristina Jironda, Pilar Hidalgo, Domingo Hern&#225;ndez Marrero, Domingo Hern&#225;ndez-Marrero"
          "autores" => array:12 [
            0 => array:2 [
              "nombre" => "Silvia"
              "apellidos" => "Ros Ruiz"
            ]
            1 => array:2 [
              "nombre" => "Silvia"
              "apellidos" => "Ros-Ruiz"
            ]
            2 => array:2 [
              "nombre" => "Pedro"
              "apellidos" => "Aranda Lara"
            ]
            3 => array:2 [
              "nombre" => "Pedro"
              "apellidos" => "Aranda-Lara"
            ]
            4 => array:2 [
              "nombre" => "Juan Carlos"
              "apellidos" => "Fern&#225;ndez"
            ]
            5 => array:2 [
              "nombre" => "Juan C&#46;"
              "apellidos" => "Fern&#225;ndez"
            ]
            6 => array:2 [
              "nombre" => "Maria Dolores"
              "apellidos" => "Mart&#237;nez Esteban"
            ]
            7 => array:2 [
              "nombre" => "M&#46; Dolores"
              "apellidos" => "Mart&#237;nez-Esteban"
            ]
            8 => array:2 [
              "nombre" => "Cristina"
              "apellidos" => "Jironda"
            ]
            9 => array:2 [
              "nombre" => "Pilar"
              "apellidos" => "Hidalgo"
            ]
            10 => array:2 [
              "nombre" => "Domingo"
              "apellidos" => "Hern&#225;ndez Marrero"
            ]
            11 => array:2 [
              "nombre" => "Domingo"
              "apellidos" => "Hern&#225;ndez-Marrero"
            ]
          ]
        ]
      ]
    ]
    "idiomaDefecto" => "en"
    "Traduccion" => array:1 [
      "es" => array:9 [
        "pii" => "X0211699512000925"
        "doi" => "10.3265/Nefrologia.pre2011.Nov.10962"
        "estado" => "S300"
        "subdocumento" => ""
        "abierto" => array:3 [
          "ES" => true
          "ES2" => true
          "LATM" => true
        ]
        "gratuito" => true
        "lecturas" => array:1 [
          "total" => 0
        ]
        "idiomaDefecto" => "es"
        "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/X0211699512000925?idApp=UINPBA000064"
      ]
    ]
    "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/X2013251412000922?idApp=UINPBA000064"
    "url" => "/20132514/0000003200000002/v0_201502091616/X2013251412000922/v0_201502091616/en/main.assets"
  ]
  "en" => array:15 [
    "idiomaDefecto" => true
    "titulo" => "Chronic kidney disease progression in patients with autosomal dominant polycystic kidney disease"
    "tieneTextoCompleto" => true
    "paginas" => array:1 [
      0 => array:2 [
        "paginaInicial" => "197"
        "paginaFinal" => "205"
      ]
    ]
    "autores" => array:1 [
      0 => array:3 [
        "autoresLista" => "Nayara Panizo, Marian Goicoechea, Soledad Garc&#237;a de Vinuesa, David Arroyo, Claudia Yuste, Abraham Rinc&#243;n, Ursula Verdalles, Caridad Ruiz-Caro, Borja Quiroga, Jos&#233; Lu&#241;o"
        "autores" => array:16 [
          0 => array:4 [
            "nombre" => "Nayara"
            "apellidos" => "Panizo"
            "email" => array:1 [
              0 => "nayapanizo&#64;gmail&#46;com"
            ]
            "referencia" => array:1 [
              0 => array:2 [
                "etiqueta" => "<span class="elsevierStyleSup">a</span>"
                "identificador" => "affa"
              ]
            ]
          ]
          1 => array:4 [
            "nombre" => "Nayara"
            "apellidos" => "Panizo"
            "email" => array:1 [
              0 => "nayapanizo&#64;gmail&#46;com"
            ]
            "referencia" => array:1 [
              0 => array:2 [
                "etiqueta" => "<span class="elsevierStyleSup">b</span>"
                "identificador" => "affb"
              ]
            ]
          ]
          2 => array:3 [
            "nombre" => "Marian"
            "apellidos" => "Goicoechea"
            "referencia" => array:1 [
              0 => array:2 [
                "etiqueta" => "<span class="elsevierStyleSup">a</span>"
                "identificador" => "affa"
              ]
            ]
          ]
          3 => array:3 [
            "nombre" => "Marian"
            "apellidos" => "Goicoechea"
            "referencia" => array:1 [
              0 => array:2 [
                "etiqueta" => "<span class="elsevierStyleSup">b</span>"
                "identificador" => "affb"
              ]
            ]
          ]
          4 => array:3 [
            "nombre" => "Soledad"
            "apellidos" => "Garc&#237;a de Vinuesa"
            "referencia" => array:1 [
              0 => array:2 [
                "etiqueta" => "<span class="elsevierStyleSup">b</span>"
                "identificador" => "affb"
              ]
            ]
          ]
          5 => array:3 [
            "nombre" => "David"
            "apellidos" => "Arroyo"
            "referencia" => array:1 [
              0 => array:2 [
                "etiqueta" => "<span class="elsevierStyleSup">a</span>"
                "identificador" => "affa"
              ]
            ]
          ]
          6 => array:3 [
            "nombre" => "David"
            "apellidos" => "Arroyo"
            "referencia" => array:1 [
              0 => array:2 [
                "etiqueta" => "<span class="elsevierStyleSup">b</span>"
                "identificador" => "affb"
              ]
            ]
          ]
          7 => array:3 [
            "nombre" => "Claudia"
            "apellidos" => "Yuste"
            "referencia" => array:1 [
              0 => array:2 [
                "etiqueta" => "<span class="elsevierStyleSup">a</span>"
                "identificador" => "affa"
              ]
            ]
          ]
          8 => array:3 [
            "nombre" => "Claudia"
            "apellidos" => "Yuste"
            "referencia" => array:1 [
              0 => array:2 [
                "etiqueta" => "<span class="elsevierStyleSup">b</span>"
                "identificador" => "affb"
              ]
            ]
          ]
          9 => array:3 [
            "nombre" => "Abraham"
            "apellidos" => "Rinc&#243;n"
            "referencia" => array:1 [
              0 => array:2 [
                "etiqueta" => "<span class="elsevierStyleSup">a</span>"
                "identificador" => "affa"
              ]
            ]
          ]
          10 => array:3 [
            "nombre" => "Abraham"
            "apellidos" => "Rinc&#243;n"
            "referencia" => array:1 [
              0 => array:2 [
                "etiqueta" => "<span class="elsevierStyleSup">b</span>"
                "identificador" => "affb"
              ]
            ]
          ]
          11 => array:3 [
            "nombre" => "Ursula"
            "apellidos" => "Verdalles"
            "referencia" => array:1 [
              0 => array:2 [
                "etiqueta" => "<span class="elsevierStyleSup">a</span>"
                "identificador" => "affa"
              ]
            ]
          ]
          12 => array:3 [
            "nombre" => "Ursula"
            "apellidos" => "Verdalles"
            "referencia" => array:1 [
              0 => array:2 [
                "etiqueta" => "<span class="elsevierStyleSup">b</span>"
                "identificador" => "affb"
              ]
            ]
          ]
          13 => array:3 [
            "nombre" => "Caridad"
            "apellidos" => "Ruiz-Caro"
            "referencia" => array:1 [
              0 => array:2 [
                "etiqueta" => "<span class="elsevierStyleSup">c</span>"
                "identificador" => "affc"
              ]
            ]
          ]
          14 => array:3 [
            "nombre" => "Borja"
            "apellidos" => "Quiroga"
            "referencia" => array:1 [
              0 => array:2 [
                "etiqueta" => "<span class="elsevierStyleSup">b</span>"
                "identificador" => "affb"
              ]
            ]
          ]
          15 => array:3 [
            "nombre" => "Jos&#233;"
            "apellidos" => "Lu&#241;o"
            "referencia" => array:1 [
              0 => array:2 [
                "etiqueta" => "<span class="elsevierStyleSup">b</span>"
                "identificador" => "affb"
              ]
            ]
          ]
        ]
        "afiliaciones" => array:3 [
          0 => array:3 [
            "entidad" => "Servicio de Nefrología, Hospital General Universitario Gregorio Marañón, Madrid,  Spain, "
            "etiqueta" => "<span class="elsevierStyleSup">a</span>"
            "identificador" => "affa"
          ]
          1 => array:3 [
            "entidad" => "Servicio de Nefrología, Hospital General Universitario Gregorio Marañón, Madrid,   "
            "etiqueta" => "<span class="elsevierStyleSup">b</span>"
            "identificador" => "affb"
          ]
          2 => array:3 [
            "entidad" => " Clínica Dialcentro, Madrid,   "
            "etiqueta" => "<span class="elsevierStyleSup">c</span>"
            "identificador" => "affc"
          ]
        ]
      ]
    ]
    "titulosAlternativos" => array:1 [
      "es" => array:1 [
        "titulo" => "Progresi&#243;n de la enfermedad renal cr&#243;nica en pacientes con enfermedad poliqu&#237;stica autos&#243;mica dominante"
      ]
    ]
    "resumenGrafico" => array:2 [
      "original" => 0
      "multimedia" => array:8 [
        "identificador" => "fig1"
        "etiqueta" => "Tab.  1"
        "tipo" => "MULTIMEDIAFIGURA"
        "mostrarFloat" => true
        "mostrarDisplay" => false
        "copyright" => "Elsevier Espa&#241;a"
        "figura" => array:1 [
          0 => array:4 [
            "imagen" => "11177_16025_26764_en_t1_11177.jpg"
            "Alto" => 477
            "Ancho" => 1063
            "Tamanyo" => 744603
          ]
        ]
        "descripcion" => array:1 [
          "en" => "Baseline patient characteristics &#40;qualitative variables&#41;"
        ]
      ]
    ]
    "textoCompleto" => "<p class="elsevierStylePara"><span class="elsevierStyleBold">INTRODUCTION</span></p><p class="elsevierStylePara">&#160;</p><p class="elsevierStylePara">Autosomal dominant polycystic kidney disease &#40;ADPKD&#41; is one of the most common hereditary diseases observed and the most frequent genetic cause of chronic kidney disease &#40;CKD&#41;&#46;<span class="elsevierStyleSup">1-3</span> This disease affects one out of every 800-1000 people in the global population&#44; and constitutes the aetiology for terminal chronic kidney disease &#40;TCKD&#41; in 5&#37;-10&#37; of patients on extra-renal purification programmes&#46;<span class="elsevierStyleSup">4</span></p><p class="elsevierStylePara">Despite the importance of this health issue&#44; it was not been the subject of much research until recent years&#44; when several studies were performed with the objective of identifying predictive factors for a rapid progression of renal disease&#46;<span class="elsevierStyleSup">5-7</span> Some of these factors can be modified by using different therapeutic interventions that are currently under study&#44; such as tolvaptan&#44;<span class="elsevierStyleSup">8&#44;9</span> m-TOR &#40;mammalian target of rapamycin&#41; inhibitors&#44;<span class="elsevierStyleSup">10</span> somatostatin analogues&#44;<span class="elsevierStyleSup">11</span> and even rosiglitazone&#44;<span class="elsevierStyleSup">12</span> which have been used successfully in animal models&#46;</p><p class="elsevierStylePara">Among the factors that have been identified in the progression of ADPKD&#44; the most important one is hypertension&#44;<span class="elsevierStyleSup">8&#44;14</span> but other possible factors for the progression of disease have been identified&#44; such as African American race&#44;<span class="elsevierStyleSup">15</span> male sex&#44; haematuria&#44; proteinuria&#44; renal cyst volume&#44; and polycystin 1 &#40;PKD1&#41; vs polycystin 2 &#40;PKD2&#41; mutations&#46;<span class="elsevierStyleSup">1</span></p><p class="elsevierStylePara">The objective of our study was to perform a retrospective analysis of the factors that influence the progression of chronic renal failure in incident patients with ADPKD treated at our department throughout the last 13 years&#46;</p><p class="elsevierStylePara">Our study&#44; which dealt with patients at a single centre and thus a small sample size&#44; stands out for the long follow-up period that&#44; although was retrospective in nature&#44; has been surpassed by only a few studies published to date&#46; In contrast to other studies&#44; the importance of systolic &#40;SBP&#41; as opposed to diastolic &#40;DBP&#41; blood pressure stands out as a factor for the progression of renal failure in these patients&#46; Additionally&#44; we have underlined the prognostic importance of age at diagnosis as a possible variable suggestive of which type of genetic mutation is present&#46; As such&#44; our study provides a simple and practical focus for the evaluation of the risk of rapid progression towards TCKD&#46; We have also evaluated the role of other factors of progression such as dyslipidemia and hyperuricemia&#44; which have been poorly studied until now&#46;</p><p class="elsevierStylePara">&#160;</p><p class="elsevierStylePara"><span class="elsevierStyleBold">MATERIAL AND METHOD</span></p><p class="elsevierStylePara">&#160;</p><p class="elsevierStylePara">We included a total of 101 patients that were monitored at our clinic from 1997 to the present&#46; Patients had been diagnosed with ADPKD based on standardised radiological criteria&#46;<span class="elsevierStyleSup">16</span> Patients with ADPKD with less than two visits to our practice were excluded&#44; whether because the patient abandoned the follow-up protocol or when a renal event occurred within the first year after diagnosis&#46;</p><p class="elsevierStylePara">At each visit&#44; we collected demographical variables&#44; SBP and DBP values&#44; concomitant medications&#44; haemoglobin&#44; creatinine &#40;Cr&#41;&#44; uric acid&#44; total cholesterol&#44; HDL-cholesterol&#44; LDL-cholesterol&#44; triglycerides&#44; calcium&#44; phosphorous&#44; parathyroid hormone &#40;PTH&#41;&#44; proteinuria&#44; and haematuria&#46; Biochemical variables were measured using standard methods&#46; PTH was measured using IRMA &#40;intact 10-60pg&#47;ml molecule&#44; Allegro Nichols&#41;&#46; Albuminuria was measured in 24-hour urine samples using immunonephelometric methods&#46; Haematuria was defined in urine sediments as the presence of more than three red blood cells per microscopic field in at least two of three correctly collected samples&#46;<span class="elsevierStyleSup">17 </span>Kidney size &#40;cm&#41; was measured using renal ultrasound&#46; Although each patient underwent several ultrasounds throughout the follow-up period&#44; only baseline values were taken into account for the analysis&#44; both for the largest renal cyst and maximum kidney diameter in centimetres&#46; Since this was a retrospective analysis&#44; we did not have an initially standardised methodology for taking measurements&#44; and multiple professionals performed the procedures&#46; Over the 13 years of the study&#44; different radiologists evaluated the ultrasounds &#40;three different doctors evaluated the majority of images&#41;&#46; Inter and intra-observer variability was not taken into account&#46;</p><p class="elsevierStylePara">Blood pressure &#40;BP&#41; was measured using an automatic sphygmanometer in accordance with the recommendations of the Spanish Society of Hypertension&#46;<span class="elsevierStyleSup">18</span> Patients were considered hypertensive when SBP and DBP were equal to or greater than 140mm Hg and 90mm Hg&#44; respectively&#44; or if they were receiving anti-hypertensive drugs&#46; The treatment objective was set at 130&#47;80mm Hg&#44; in accordance with the recommendations of the seventh report of the JNC &#40;Joint National Committee on Prevention&#44; Detection&#44; Evaluation&#44; and Treatment of High Blood Pressure&#41;&#46;<span class="elsevierStyleSup">19</span></p><p class="elsevierStylePara">Dyslipidemia was defined as total cholesterol greater than 200mg&#47;dl and LDL-cholesterol greater than 130mg&#47;dl&#44; in accordance with the European guidelines for cardiovascular prevention&#44;<span class="elsevierStyleSup">20</span> or if the patient was receiving lipid lowering treatment&#46;</p><p class="elsevierStylePara">Renal function was evaluated as estimated glomerular filtration rate &#40;eGFR&#41; using the CKD-EPI formula&#46;<span class="elsevierStyleSup">21</span></p><p class="elsevierStylePara">We analysed the progression renal failure using the following two methods&#58;</p><p class="elsevierStylePara">1&#41; Based on the appearance of a renal event&#44; defined as a 50&#37; reduction in eGFR as measured by CKD-EPI from the initial values from the outpatient visit and&#47;or entrance to dialysis&#46;</p><p class="elsevierStylePara">2&#41; Based on mean change in eGFR&#47;year&#46; According to the decrease in eGFR&#47;year above or below the mean&#44; we defined two different groups&#58; group A&#58; patients with a fast progression of CKD&#59; and group B&#58; patients with a normal progression of CKD&#46;</p><p class="elsevierStylePara">Patients diagnosed with ADPKD were included in the study from the moment of their first visit with a nephrologist&#44; considering all measurements from this consultation as baseline values&#44; until a renal event occurred&#46; Data were compiled on an annual basis&#44; with the number of visits ranging between 1 and 10&#46; The longest follow-up period lasted 13 years&#46; The median follow-up time was 69 &#40;35-128&#41; months&#46;</p><p class="elsevierStylePara">Values are expressed as mean &#177; SD &#40;standard deviation&#41; or median &#40;interquartile range&#41; if the variables did not follow a normal distribution&#46; We used the Kolmogorov-Smirnov test to evaluate normal distribution for the different parameters assessed&#46; For the analysis of differences between patients that suffered a renal event and those that did not&#44; we used chi-square tests for qualitative variables and Student&#8217;s t-tests or Mann-Whitney U-tests for quantitative variables with a normal distribution or non-Gaussian distribution&#44; respectively&#46; We assumed that a difference was statistically significant when <span class="elsevierStyleItalic">P</span>&#60;&#46;05&#46;</p><p class="elsevierStylePara">We performed a multivariate linear regression analysis using the variables that influenced annual change in eGFR&#46; The prognostic value of the predictive factors for the appearance of renal events or rapid progression towards CKD was evaluated using a Cox regression multivariate model&#46; We introduced all covariates into the multivariate model that had a predictive power for renal events or rapid progression in the univariate model with a <span class="elsevierStyleItalic">P</span>&#60;&#46;01&#46; The regression coefficients and their SD were calculated using SPSS software&#44; version 16&#46;0 &#40;Chicago&#44; IL&#41;&#46;</p><p class="elsevierStylePara"><span class="elsevierStyleBold">&#160;</span></p><p class="elsevierStylePara"><span class="elsevierStyleBold">RESULTS</span></p><p class="elsevierStylePara">&#160;</p><p class="elsevierStylePara">Our study included a total of 101 patients&#44; 44 of which were male and 57 of which were female&#46; The mean age was 43&#46;5&#177;17&#46;2 years&#46; The baseline characteristics for these patients are collected in Tables 1 and 2&#46;</p><p class="elsevierStylePara">Figure 1 displays the evolution of eGFR &#40;ml&#47;min&#47;1&#46;73m<span class="elsevierStyleSup">2</span>&#41; in all patients and in the two different groups of disease progression&#46;</p><p class="elsevierStylePara">Figure 2 displays the evolution of SBP and DBP values throughout the follow-up period&#46; A total of 41&#46;4&#37; of patients were already receiving antihypertensive treatment with angiotensin-converting enzyme &#40;ACE&#41; inhibitors or angiotensin receptor blockers &#40;ARB&#41; at the start of the follow-up period&#46; Throughout the study period&#44; 16&#46;9&#37; of patients started treatment with ACE inhibitors and 15&#46;7&#37; with ARB&#44; such that 74&#37; of patients received antihypertensive treatment over the course of the study&#46;</p><p class="elsevierStylePara">During the study period&#44; 31 patients suffered a renal event&#46; The median time of follow-up between the baseline visit and the event was 102 months &#40;range&#58; 53-131 months&#41;&#46; The univariate analysis showed that patients that suffered a renal event had higher baseline SBP&#44; DBP&#44; uric acid&#44; total cholesterol&#44; LDL-cholesterol&#44; baseline Cr&#44; proteinuria&#44; and larger kidney size &#40;Table 3&#41;&#46; There were significant differences in mean initial eGFR between the two groups&#44; with 82&#46;5&#177;34&#46;2ml&#47;min&#47;1&#46;73m<span class="elsevierStyleSup">2</span> in the group of patients that did not suffer a renal event&#44; and 59&#46;8&#177;22&#46;7ml&#47;min&#47;1&#46;73m<span class="elsevierStyleSup">2</span> in the group that did &#40;<span class="elsevierStyleItalic">P</span>&#61;&#46;01&#41;&#46; We observed no significant differences between groups for variables such as haematocrit&#44; calcium&#44; phosphorous&#44; HDL-cholesterol&#44; and triglycerides &#40;results not shown in the table&#41;&#46;</p><p class="elsevierStylePara">In the Cox regression model adjusted for baseline renal function&#44; proteinuria&#44; uric acid&#44; BP&#44; and cholesterol&#44; SBP was the variable that maintained its predictive value for a renal event&#46;</p><p class="elsevierStylePara">The mean annual change in GFR in the overall group of patients was -3&#46;52&#177;7&#46;3ml&#47;min&#47;1&#46;73m<span class="elsevierStyleSup">2</span>&#46; In the multivariate linear regression model&#44; change in GFR was independently correlated with SBP &#40;&#946;&#61;-6&#46;7x10<span class="elsevierStyleSup">-2</span>&#44; <span class="elsevierStyleItalic">P</span>&#61;&#46;03&#41;&#46;</p><p class="elsevierStylePara">We identified 49 patients with rapid disease progression &#40;decrease &#62;3&#46;52ml&#47;min&#47;1&#46;73m<span class="elsevierStyleSup">2</span>&#41;&#58; group A&#44; and 52 patients with normal progression &#40;less than 3&#46;52ml&#47;min&#47;1&#46;73m<span class="elsevierStyleSup">2</span>&#41;&#58; group B&#46; There were no significant differences between the two groups in terms of initial eGFR&#44; which was 74&#46;1&#177;32&#46;7ml&#47;min&#47;1&#46;73m<span class="elsevierStyleSup">2</span> in the group with normal progression&#44; and 76&#46;7&#177;32&#46;6ml&#47;min&#47;1&#46;73m<span class="elsevierStyleSup">2</span> in the rapid progression group &#40;<span class="elsevierStyleItalic">P</span>&#62;&#46;05&#41;&#46; Group A patients had higher baseline SBP and proteinuria &#40;Table 4&#41;&#46; The logistic regression analysis revealed that the predictive variable for a rapid disease progression was still SBP&#44; with the addition of a younger age at the first consultation&#44; regardless of proteinuria&#44; sex&#44; initial renal function&#44; and DBP &#40;Table 5&#41;&#46;</p><p class="elsevierStylePara">&#160;</p><p class="elsevierStylePara"><span class="elsevierStyleBold">DISCUSSION</span></p><p class="elsevierStylePara">&#160;</p><p class="elsevierStylePara">The primary result of our study&#44; with a cohort of stable patients diagnosed with ADPKD and evaluated in nephrological consultations&#44; was the confirmation that systolic arterial hypertension and a younger age at diagnosis are the most important factors that influence the long-term progression of renal failure&#46;</p><p class="elsevierStylePara">Many recent studies on ADPKD have focused on the importance of renal volume as a determining factor in the deterioration of renal function&#44; which advances parallel to the increase in cyst sizes&#46;<span class="elsevierStyleSup">22</span> There are also other studies that correlate clinical and biochemical parameters with kidney size and glomerular filtration rate&#46;<span class="elsevierStyleSup">5</span> However&#44; there are few examples in the literature that correlate a patient&#8217;s baseline clinical characteristics with long-term clinical evolution as our study has&#46; Recently&#44; a retrospective cohort study was published with a follow-up period of 22 years&#44; including 194 patients with ADPKD&#44; which analysed the influence of mutation type on clinical characteristics and the development of renal events&#46;<span class="elsevierStyleSup">23</span> Cyst growth appears to be one of the most important factors in determining the progression of CKD in these patients&#46; As such&#44; in many clinical trials focusing on therapeutic interventions&#44; cyst growth has been used as the reference marker for identifying patients that could benefit from treatment&#46;<span class="elsevierStyleSup">5&#44;24</span> However&#44; one of the most reliable methods for measuring renal structure and volume&#44; standard magnetic resonance&#44;<span class="elsevierStyleSup">25 </span>is an expensive method that is not available in all hospitals and requires a large amount of time from the radiologist&#46; A similar pattern occurs in computed tomography&#44; which has been employed in volumetric measurements&#44; with good correlation with total renal volume&#44; renal cyst volume&#44; and decrease in eGFR&#46;<span class="elsevierStyleSup">26&#44;27</span> Some authors have indicated that the deterioration in renal function does not depend on cyst volume as much as on the amount of intermediate tissue in polycystic kidneys measured by computed tomography&#46;<span class="elsevierStyleSup">28</span> Other methods of measurement such as ultrasound do not provide as good a correlation for renal function&#44;<span class="elsevierStyleSup">27</span> and so we need other variables from our clinical practice that aid in identifying patients that would benefit from early treatment&#46; In our study&#44; we evaluated kidney size using ultrasound&#44; which was an imprecise method&#44; taking into account that the measurements were taken by various radiologists&#46; Although the univariate analysis revealed a difference in kidney size between patients that had a renal event and those that did not&#44; this variable did not retain its predictive value when other parameters were adjusted for&#46;</p><p class="elsevierStylePara">As such&#44; in routine clinical practice&#44; it would be very beneficial to have access to markers&#44; aside from cyst growth&#44; that would identify patients who&#44; starting at an early age&#44; will suffer a rapid progression in their kidney disease&#44; and as such will be candidates for more aggressive therapeutic options&#44; when sufficient evidence exists in the literature to support their use&#46;</p><p class="elsevierStylePara">Arterial hypertension is a common clinical manifestation in patients with ADPKD&#46; A recent demographic study performed in Turkey with 1139 patients with ADPKD identified this as the most common clinical manifestation in these patients&#44; as it was present in 76&#37; of cases&#46;<span class="elsevierStyleSup">29</span> It commonly occurs early on&#44; before the appearance of deteriorated renal function in 60&#37; of cases&#46;<span class="elsevierStyleSup">30</span> Several studies have related hypertension with the speed of progression in renal disease&#46; One retrospective study with 94 patients compared rapid progression with slow progression patients&#44; finding that those who progressed faster had a higher incidence of hypertension&#44; haematuria&#44; proteinuria&#44; and urinary infections&#46;<span class="elsevierStyleSup">31</span> Another study points out that hypertensive patients with ADPKD have worse renal function than normotensive patients&#44; with an added increase in cardiovascular risk&#46;<span class="elsevierStyleSup">32</span> There have also been studies showing a lower mortality rate<span class="elsevierStyleSup">33</span> and a progressive delay in the age at which these patients reach TCKD&#44; relating this to a progressively better control of blood pressure levels in recent years&#44;<span class="elsevierStyleSup">1&#44;34</span> especially from the use of ACE inhibitors and ARB&#44; although no differences have been found between the two drugs in controlling BP and Cr values in these patients&#46;<span class="elsevierStyleSup">35</span> In a recently published study in Spain&#44; kidney size was correlated with a pathological profile involving BP as measured in outpatient monitoring programmes&#44; highlighting a greater variability in BP&#44; especially diastolic&#44; and lower pulse pressure with greater kidney size&#44; as measured using ultrasound&#44; even in a stage of pre-hypertension&#46;<span class="elsevierStyleSup">36</span> Our study corroborated these findings&#44; with the novel result that it is SBP&#44; not DBP&#44; that maintains its independent predictive value for the rapid progression of kidney disease&#44; which is in agreement with the results from other studies&#44; such as the report by Cadnapaphornchai et al&#46;&#44;<span class="elsevierStyleSup">37</span> which analysed the association between renal volume&#44; SBP and DBP&#44; and left ventricular mass index in patients with ADPKD&#46; As in our case&#44; they detected an association between both BP variables and renal volume in the univariate analysis&#44; but only SBP remained after adjusting for age and sex in the multivariate analysis&#46;</p><p class="elsevierStylePara">The percentage of patients that were already receiving treatment with renin-angiotensin-aldosterone system &#40;RAAS&#41; blockers at the start of treatment was 41&#46;4&#37;&#59; 32&#46;6&#37; started treatment with these drugs during the follow-up period&#46; In total&#44; 74&#37; received treatment with RAAS blockers over the study period&#46; We observed no differences between patients receiving this treatment and those that did not&#44; whether in terms of the appearance of renal events or the speed of progression&#46; However&#44; it is well known that control of BP levels&#44; especially systolic&#44; is a fundamental factor for slowing the progression of kidney disease&#44; not only in ADPKD&#44; but in CKD in general&#44; as demonstrated by several studies&#46;<span class="elsevierStyleSup">38-40 </span>In the specific case of ADPKD&#44; the HALT study is currently under way&#44; with the goal of elucidating the potential benefit of strict BP control using RAAS blockers in slowing the progression of TCKD&#46;<span class="elsevierStyleSup">41</span></p><p class="elsevierStylePara">In the univariate analysis&#44; we found that patients with a renal event or rapid disease progression had higher initial proteinuria values than those with a slow disease progression&#47;absence of renal events&#46; However&#44; this variable did not maintain its predictive value in the Cox regression analysis&#44; despite the fact that proteinuria is a known factor for the progression of kidney disease&#46;<span class="elsevierStyleSup">42</span> This fact was probably due to the low values of proteinuria displayed by our patients &#40;median&#58; 19&#46;75&#59; IQR&#58; 0-58&#46;5&#41;&#44; as proteinuria is an uncharacteristic manifestation of this disease&#46;</p><p class="elsevierStylePara">Our second notable finding was that younger patients had a higher rate of decrease in eGFR&#46; These results concur with those from Torres et al&#46;&#44; who showed that a younger age at diagnosis is associated with a greater increase in total renal volume&#44; and this&#44; in turn&#44; is correlated with a greater rate of decrease in glomerular filtration rate&#46;<span class="elsevierStyleSup">5</span> Although we did not perform a genetic study&#44; we can put this finding in the context of the higher probability that these patients have a mutation on the PKD1 gene&#44; which tends to produce a greater pathological repercussion and earlier deterioration in renal function&#46;<span class="elsevierStyleSup">43&#44;44</span> These results are supported by those from the genetic study by Torra et al&#46;&#44; which found that&#44; in patients with ADPKD that had not reached TCKD by the age of 63 years&#44; the prevalence of PKD2 mutations was three times higher than the estimated proportion for the general population with ADPKD&#46;<span class="elsevierStyleSup">45</span> Other studies also coincide on the finding that&#44; in families diagnosed with the disease in which at least one member reached TCKD at an age younger than 55&#44; there is a high probability that the mutation is on the PKD1 gene&#46;<span class="elsevierStyleSup">46</span></p><p class="elsevierStylePara">Our results also demonstrate the importance of controlling other cardiovascular risk factors&#44; such as cholesterol and uric acid&#44; both for the progression of CKD in patients with ADPKD and in other renal pathologies&#46; Although these parameters do not independently influence the progression of renal failure&#44; they do appear to be important and controllable variables in the appearance of renal events in the univariate analysis&#46; Several studies have suggested that ADPKD produces an increase in uric acid levels associated with decreased renal function&#44;<span class="elsevierStyleSup">47</span> but there are no data regarding the influence of uric acid levels on the progression of the kidney disease in this particular case&#46; However&#44; in recent years&#44; the relationship between hyperuricemia and the progression of CKD has been investigated&#44;<span class="elsevierStyleSup">48&#44;49</span> and recently the use of uric acid lowering drugs &#40;allopurinol&#41; has been shown to reduce disease progression&#46;<span class="elsevierStyleSup">50</span> As regards lipid control&#44; several studies have indicated that lower HDL-cholesterol levels are correlated with increased deterioration of renal function&#44;<span class="elsevierStyleSup">5</span> although we have not found data in the literature that show the influence of LDL-cholesterol levels on renal function in patients with ADPKD&#46; Even so&#44; the fact that patients with worse cholesterol levels have more renal events supports the hypothesis held by some trials that have attempted to show that renal function in these patients could be improved by using statins&#44; through an increase in renal plasma flow derived from improved endothelial function&#46;<span class="elsevierStyleSup">51</span></p><p class="elsevierStylePara">Our study is not without its limitations&#46; The primary limitation in our case was that&#44; while the study design was a prospective&#44; longitudinal type&#44; the data collection was retrospective&#44; with the inherent drawbacks from the point of view of data analysis&#44; and so we can only show evidence of an association between systolic hypertension and increased disease progression&#46; Additionally&#44; the sample was not sufficiently large due to the fact that our data were derived from one single centre&#46; However&#44; despite the small sample size&#44; the extremely long follow-up period has been surpassed by only a few isolated studies available in the medical literature&#44;<span class="elsevierStyleSup">1&#44;33&#44;34</span> which bolsters the validity of our results&#46; We should also point out the limitations of the absence of a genetic analysis&#44; along with the use of renal ultrasound instead of a computed tomography or nuclear magnetic resonance for the evaluation of initial renal volume&#46;</p><p class="elsevierStylePara">We can conclude that a younger age at diagnosis and higher SBP values are the two factors associated with a greater progression of renal disease in our patients with ADPKD&#46; These two variables&#44; which are easily measured&#44; allow us to detect patients that have a high probability of a faster progression towards TCKD in centres that do not have easy access to genetic analyses or magnetic resonance&#46; This in turn provides the possibility of selecting these patients as candidates for possible future treatments that show long-term advantages in slowing the progression towards the need for extra-renal purification&#46; Interventional studies are needed to establish the potential benefit of controlling SBP values&#44; cholesterol&#44; and uric acid in slowing the progression towards TCKD in these patients&#46;</p><p class="elsevierStylePara"><span class="elsevierStyleBold">&#160;</span></p><p class="elsevierStylePara"><span class="elsevierStyleBold">Conflicts of Interest</span></p><p class="elsevierStylePara">&#160;</p><p class="elsevierStylePara">The authors have no potential conflicts of interest related to the content of this article to declare&#46;</p><p class="elsevierStylePara"><a href="grande&#47;11177&#95;16025&#95;26764&#95;en&#95;t1&#95;11177&#46;jpg" class="elsevierStyleCrossRefs"><img src="11177_16025_26764_en_t1_11177.jpg" alt="Baseline patient characteristics &#40;qualitative variables&#41;"></img></a></p><p class="elsevierStylePara">Table 1&#46; Baseline patient characteristics &#40;qualitative variables&#41;</p><p class="elsevierStylePara"><a href="grande&#47;11177&#95;16025&#95;26765&#95;en&#95;t2&#95;11177&#46;jpg" class="elsevierStyleCrossRefs"><img src="11177_16025_26765_en_t2_11177.jpg" alt="Baseline patient characteristics &#40;quantitative variables&#41;"></img></a></p><p class="elsevierStylePara">Table 2&#46; Baseline patient characteristics &#40;quantitative variables&#41;</p><p class="elsevierStylePara"><a href="grande&#47;11177&#95;16025&#95;26766&#95;en&#95;t3&#95;11177&#46;jpg" class="elsevierStyleCrossRefs"><img src="11177_16025_26766_en_t3_11177.jpg" alt="Predictive factors for renal events&#46; Univariate analysis"></img></a></p><p class="elsevierStylePara">Table 3&#46; Predictive factors for renal events&#46; Univariate analysis</p><p class="elsevierStylePara"><a href="grande&#47;11177&#95;16025&#95;26768&#95;en&#95;t4&#95;11177&#46;jpg" class="elsevierStyleCrossRefs"><img src="11177_16025_26768_en_t4_11177.jpg" alt="Predictive factors for a rapid progression in kidney disease&#46; Univariate analysis &#40;Student’s t-test&#41;"></img></a></p><p class="elsevierStylePara">Table 4&#46; Predictive factors for a rapid progression in kidney disease&#46; Univariate analysis &#40;Student’s t-test&#41;</p><p class="elsevierStylePara"><a href="grande&#47;11177&#95;16025&#95;26769&#95;en&#95;t5&#95;11177&#46;jpg" class="elsevierStyleCrossRefs"><img src="11177_16025_26769_en_t5_11177.jpg" alt="Predictive variables for a rapid progression in kidney disease&#46; Logistic regression"></img></a></p><p class="elsevierStylePara">Table 5&#46; Predictive variables for a rapid progression in kidney disease&#46; Logistic regression</p><p class="elsevierStylePara"><a href="grande&#47;11177&#95;16025&#95;26770&#95;en&#95;f1&#95;11177&#46;jpg" class="elsevierStyleCrossRefs"><img src="11177_16025_26770_en_f1_11177.jpg" alt="Decrease in glomerular filtration rate in all patients and in the two different groups of disease progression"></img></a></p><p class="elsevierStylePara">Figure 1&#46; Decrease in glomerular filtration rate in all patients and in the two different groups of disease progression</p><p class="elsevierStylePara"><a href="grande&#47;11177&#95;16025&#95;26771&#95;en&#95;f2&#95;&#95;11177&#46;jpg" class="elsevierStyleCrossRefs"><img src="11177_16025_26771_en_f2__11177.jpg" alt="Evolution over time of SBP and DBP values during follow-up&#46; Mean &#40;SD&#41;"></img></a></p><p class="elsevierStylePara">Figure 2&#46; Evolution over time of SBP and DBP values during follow-up&#46; Mean &#40;SD&#41;</p>"
    "pdfFichero" => "P1-E534-S3437-A11177-EN.pdf"
    "tienePdf" => true
    "PalabrasClave" => array:2 [
      "es" => array:1 [
        0 => array:4 [
          "clase" => "keyword"
          "titulo" => "Palabras clave"
          "identificador" => "xpalclavsec438735"
          "palabras" => array:1 [
            0 => "Enfermedades renales poliqu&#237;sticas"
          ]
        ]
      ]
      "en" => array:1 [
        0 => array:4 [
          "clase" => "keyword"
          "titulo" => "Keywords"
          "identificador" => "xpalclavsec438736"
          "palabras" => array:1 [
            0 => "Polycystic kidney diseases"
          ]
        ]
      ]
    ]
    "tieneResumen" => true
    "resumen" => array:2 [
      "es" => array:1 [
        "resumen" => "<p class="elsevierStylePara"><span class="elsevierStyleBold">Objetivos&#58;</span>&#160;El objetivo del presente estudio es analizar los factores que influyen en la progresi&#243;n de la insuficiencia renal cr&#243;nica en pacientes con enfermedad poliqu&#237;stica autos&#243;mica dominante &#40;PQRAD&#41;&#46;&#160;<span class="elsevierStyleBold">Material y m&#233;todos&#58;&#160;</span>Estudiamos a 101 pacientes &#40;edad media&#58; 43&#44;6 &#177; 17&#44;3&#44; 43&#44;6&#37; varones&#41;&#46; La mediana &#40;rango intercuart&#237;lico&#41; de seguimiento es de 69 &#40;128-35&#41; meses desde 1997 hasta 2010&#46; Analizamos la progresi&#243;n de dos formas&#58; 1&#41; tiempo hasta evento renal definido como la reducci&#243;n del filtrado glomerular estimado &#40;FGe&#41; en un 50&#37; desde la primera visita y&#47;o entrada en di&#225;lisis&#44; y 2&#41; cambio medio en el FGe&#47;a&#241;o&#46; Se recogieron en cada visita datos cl&#237;nicos y demogr&#225;ficos&#44; presi&#243;n arterial sist&#243;lica &#40;PAS&#41; y diast&#243;lica &#40;PAD&#41;&#44; medicaci&#243;n concomitante y par&#225;metros anal&#237;ticos&#46; Tambi&#233;n se recogi&#243; el tama&#241;o renal basal medido por ecograf&#237;a&#46; <span class="elsevierStyleBold">Resultados&#58;</span>&#160;Treinta y un pacientes tuvieron un evento renal&#46; La mediana de tiempo hasta la aparici&#243;n del evento es de 102 &#40;131-53&#41; meses&#46; Los pacientes que tuvieron un evento renal ten&#237;an basalmente mayor PAS y PAD &#40;p &#61; 0&#44;017 y p &#61; 0&#44;001&#44; respectivamente&#41;&#44; mayores niveles de acido &#250;rico &#40;p &#61; 0&#44;041&#41;&#44; mayor colesterol LDL &#40;p &#61; 0&#44;001&#41;&#44; mayor proteinuria &#40;p &#61; 0&#44;033&#41; y mayor tama&#241;o renal &#40;p &#61; 0&#44;05&#41;&#46; El cambio medio de FGe&#47;anual fue de &#8211;3&#44;52 &#177; 7&#44;3 ml&#47;min&#47;1&#44;73 m<span class="elsevierStyleSup">2</span>&#44; 49 pacientes presentaron un descenso r&#225;pido de funci&#243;n renal&#58; Grupo A &#40;&#62; &#8211;3&#44;52 ml&#47;min&#47;1&#44;73 m<span class="elsevierStyleSup">2</span>&#41; y 52 pacientes tuvieron una progresi&#243;n lenta de la insuficiencia renal&#58; Grupo B &#40;&#60; &#8211;3&#44;2 ml&#47;min&#47;1&#44;73 m<span class="elsevierStyleSup">2</span>&#41;&#46; Por regresi&#243;n de Cox&#44; en un modelo ajustado&#44; la PAS y la menor edad al diagn&#243;stico son las variables que mantienen su poder predictivo de mal pron&#243;stico renal &#40;p &#61; 0&#44;026&#41;&#46;<span class="elsevierStyleBold">&#160;Conclusiones&#58;</span>&#160;La funci&#243;n renal inicial&#44; proteinuria&#44; tama&#241;o renal&#44; hipercolesterolemia&#44; hiperuricemia y PAS basal son factores que influyen en la progresi&#243;n de la insuficiencia renal en la PQRAD&#44; siendo la PAS y la menor edad los factores que mantienen su poder&#160; predictivo independiente en el an&#225;lisis multivariante&#46;</p>"
      ]
      "en" => array:1 [
        "resumen" => "<p class="elsevierStylePara"><span class="elsevierStyleBold">Objectives&#58;&#160;</span>The aim of this study was to analyse the factors influencing chronic kidney disease &#40;CKD&#41; progression in patients with autosomal dominant polycystic kidney disease &#40;ADPKD&#41;&#46;&#160;<span class="elsevierStyleBold">Material and Method&#58;&#160;</span>We studied 101 patients &#40;mean age&#58; 43&#177;17&#46;3 years&#44; 43&#46;56&#37; male&#41; followed during a median &#40;interquartile range&#41; follow-up time of 69 &#40;35-128&#41; months from 1997 to 2010&#46; The primary end point was&#58; time to a 50&#37; decrease of estimated glomerular filtration rate &#40;eGFR&#41; &#40;CKD-EPI&#41; since the first-time visit and&#47;or time to initiation of renal replacement therapy&#44;&#160;and the annual mean change of eGFR was also analysed&#46; Clinical and demographic data&#44; blood pressure&#44; concomitant medications&#44; and analytical parameters were collected at each visit&#46; Baseline kidney size was also recorded by ultrasound&#46; <span class="elsevierStyleBold">Results&#58; </span>Thirty-one patients achieved the primary end point after a median &#40;IQR&#41; time of 102 &#40;53-131&#41; months&#46; Those patients who achieved the primary end point had higher SBP and DBP &#40;<span class="elsevierStyleItalic">P</span>&#61;0&#46;017 and <span class="elsevierStyleItalic">P</span>&#61;0&#46;001&#41;&#44; higher LDL-cholesterol &#40;<span class="elsevierStyleItalic">P</span>&#61;0&#46;011&#41;&#44; higher creatinine &#40;<span class="elsevierStyleItalic">P</span>&#61;0&#46;006&#41;&#44; higher uricemia &#40;<span class="elsevierStyleItalic">P</span>&#61;0&#46;041&#41;&#44; more severe proteinuria &#40;<span class="elsevierStyleItalic">P</span>&#61;0&#46;033&#41; and greater kidney size &#40;<span class="elsevierStyleItalic">P</span>&#61;0&#46;05&#41;&#46; The mean annual eGFR change was of &#8211;3&#46;52&#177;7&#46;3ml&#47;min&#47;1&#46;73m<span class="elsevierStyleSup">2</span>&#46; Forty-nine patients had a rapid decline in renal function&#58; Group A &#40;higher than -3&#46;52ml&#47;min&#47;1&#46;73m<span class="elsevierStyleSup">2</span>&#41; and 52 patients had a lower renal disease progression&#58; Group B &#40;&#60;&#8211;3&#46;2 ml&#47;min&#47;1&#46;73 m<span class="elsevierStyleSup">2</span>&#41;&#46; Adjusted Cox regression analysis showed that higher SBP and younger age at the first visit were independent variables for poorer renal outcome &#40;<span class="elsevierStyleItalic">P</span>&#61;0&#46;026&#41;&#46; <span class="elsevierStyleBold">Conclusions&#58; </span>Initial kidney function&#44; proteinuria&#44; renal size&#44; hypercholesterolemia&#44; hyperuricemia&#44; and SBP are the factors that influence CKD progression in ADPKD&#46; SBP and younger age at diagnosis are the only factors that maintain their independent predictive value in a multivariant analysis&#46;</p>"
      ]
    ]
    "multimedia" => array:7 [
      0 => array:8 [
        "identificador" => "fig1"
        "etiqueta" => "Tab.  1"
        "tipo" => "MULTIMEDIAFIGURA"
        "mostrarFloat" => true
        "mostrarDisplay" => false
        "copyright" => "Elsevier Espa&#241;a"
        "figura" => array:1 [
          0 => array:4 [
            "imagen" => "11177_16025_26764_en_t1_11177.jpg"
            "Alto" => 477
            "Ancho" => 1063
            "Tamanyo" => 744603
          ]
        ]
        "descripcion" => array:1 [
          "en" => "Baseline patient characteristics &#40;qualitative variables&#41;"
        ]
      ]
      1 => array:8 [
        "identificador" => "fig2"
        "etiqueta" => "Tab.  2"
        "tipo" => "MULTIMEDIAFIGURA"
        "mostrarFloat" => true
        "mostrarDisplay" => false
        "copyright" => "Elsevier Espa&#241;a"
        "figura" => array:1 [
          0 => array:4 [
            "imagen" => "11177_16025_26765_en_t2_11177.jpg"
            "Alto" => 1266
            "Ancho" => 1054
            "Tamanyo" => 1112817
          ]
        ]
        "descripcion" => array:1 [
          "en" => "Baseline patient characteristics &#40;quantitative variables&#41;"
        ]
      ]
      2 => array:8 [
        "identificador" => "fig3"
        "etiqueta" => "Tab.  3"
        "tipo" => "MULTIMEDIAFIGURA"
        "mostrarFloat" => true
        "mostrarDisplay" => false
        "copyright" => "Elsevier Espa&#241;a"
        "figura" => array:1 [
          0 => array:4 [
            "imagen" => "11177_16025_26766_en_t3_11177.jpg"
            "Alto" => 617
            "Ancho" => 2170
            "Tamanyo" => 982331
          ]
        ]
        "descripcion" => array:1 [
          "en" => "Predictive factors for renal events&#46; Univariate analysis"
        ]
      ]
      3 => array:8 [
        "identificador" => "fig4"
        "etiqueta" => "Tab.  4"
        "tipo" => "MULTIMEDIAFIGURA"
        "mostrarFloat" => true
        "mostrarDisplay" => false
        "copyright" => "Elsevier Espa&#241;a"
        "figura" => array:1 [
          0 => array:4 [
            "imagen" => "11177_16025_26768_en_t4_11177.jpg"
            "Alto" => 273
            "Ancho" => 2164
            "Tamanyo" => 768300
          ]
        ]
        "descripcion" => array:1 [
          "en" => "Predictive factors for a rapid progression in kidney disease&#46; Univariate analysis &#40;Student’s t-test&#41;"
        ]
      ]
      4 => array:8 [
        "identificador" => "fig5"
        "etiqueta" => "Tab.  5"
        "tipo" => "MULTIMEDIAFIGURA"
        "mostrarFloat" => true
        "mostrarDisplay" => false
        "copyright" => "Elsevier Espa&#241;a"
        "figura" => array:1 [
          0 => array:4 [
            "imagen" => "11177_16025_26769_en_t5_11177.jpg"
            "Alto" => 210
            "Ancho" => 2157
            "Tamanyo" => 693428
          ]
        ]
        "descripcion" => array:1 [
          "en" => "Predictive variables for a rapid progression in kidney disease&#46; Logistic regression"
        ]
      ]
      5 => array:8 [
        "identificador" => "fig6"
        "etiqueta" => "Fig. 1"
        "tipo" => "MULTIMEDIAFIGURA"
        "mostrarFloat" => true
        "mostrarDisplay" => false
        "copyright" => "Elsevier Espa&#241;a"
        "figura" => array:1 [
          0 => array:4 [
            "imagen" => "11177_16025_26770_en_f1_11177.jpg"
            "Alto" => 964
            "Ancho" => 1880
            "Tamanyo" => 1453405
          ]
        ]
        "descripcion" => array:1 [
          "en" => "Decrease in glomerular filtration rate in all patients and in the two different groups of disease progression"
        ]
      ]
      6 => array:8 [
        "identificador" => "fig7"
        "etiqueta" => "Fig. 2"
        "tipo" => "MULTIMEDIAFIGURA"
        "mostrarFloat" => true
        "mostrarDisplay" => false
        "copyright" => "Elsevier Espa&#241;a"
        "figura" => array:1 [
          0 => array:4 [
            "imagen" => "11177_16025_26771_en_f2__11177.jpg"
            "Alto" => 944
            "Ancho" => 1013
            "Tamanyo" => 1024798
          ]
        ]
        "descripcion" => array:1 [
          "en" => "Evolution over time of SBP and DBP values during follow-up&#46; Mean &#40;SD&#41;"
        ]
      ]
    ]
    "bibliografia" => array:2 [
      "titulo" => "Bibliography"
      "seccion" => array:1 [
        0 => array:1 [
          "bibliografiaReferencia" => array:51 [
            0 => array:3 [
              "identificador" => "bib1"
              "etiqueta" => "1"
              "referencia" => array:1 [
                0 => array:3 [
                  "referenciaCompleta" => "Schrier RW, McFann KK, Johnson AM. Epidemiological study of kidney survival in autosomal dominant polycystic kidney disease., Kidney Int 2003;63(2):678-85. <a href="http://www.ncbi.nlm.nih.gov/pubmed/12631134" target="_blank">[Pubmed]</a>"
                  "contribucion" => array:1 [
                    0 => null
                  ]
                  "host" => array:1 [
                    0 => null
                  ]
                ]
              ]
            ]
            1 => array:3 [
              "identificador" => "bib2"
              "etiqueta" => "2"
              "referencia" => array:1 [
                0 => array:3 [
                  "referenciaCompleta" => "Igarashi P, Somlo S. Polycystic kidney disease. J Am Soc Nephrol 2007;18(5):1371-3. <a href="http://www.ncbi.nlm.nih.gov/pubmed/17429047" target="_blank">[Pubmed]</a>"
                  "contribucion" => array:1 [
                    0 => null
                  ]
                  "host" => array:1 [
                    0 => null
                  ]
                ]
              ]
            ]
            2 => array:3 [
              "identificador" => "bib3"
              "etiqueta" => "3"
              "referencia" => array:1 [
                0 => array:3 [
                  "referenciaCompleta" => "Cadnapaphornchai MA, George DM, Masoumi A, McFann K, Strain JD,\u{A0}Schrier RW. Effect of statin therapy on disease progression in pediatric ADPKD: design and baseline characteristics of participants. Contemp Clin Trials 2011;32(3):437-45. <a href="http://www.ncbi.nlm.nih.gov/pubmed/21266204" target="_blank">[Pubmed]</a>"
                  "contribucion" => array:1 [
                    0 => null
                  ]
                  "host" => array:1 [
                    0 => null
                  ]
                ]
              ]
            ]
            3 => array:3 [
              "identificador" => "bib4"
              "etiqueta" => "4"
              "referencia" => array:1 [
                0 => array:3 [
                  "referenciaCompleta" => "Bleyer AJ,\u{A0}Hart TC. Polycystic kidney disease. N Engl J Med 2004;350(25):2622. <a href="http://www.ncbi.nlm.nih.gov/pubmed/15201424" target="_blank">[Pubmed]</a>"
                  "contribucion" => array:1 [
                    0 => null
                  ]
                  "host" => array:1 [
                    0 => null
                  ]
                ]
              ]
            ]
            4 => array:3 [
              "identificador" => "bib5"
              "etiqueta" => "5"
              "referencia" => array:1 [
                0 => array:3 [
                  "referenciaCompleta" => "Torres VE, Grantham JJ, Chapman AB, Mrug M, Bae KT, King BF, et al. Potentially modifiable factors affecting the progression of autosomal dominant polycystic kidney disease. Clin J Am Soc Nephrol 2011;6(3):640-7. <a href="http://www.ncbi.nlm.nih.gov/pubmed/21088290" target="_blank">[Pubmed]</a>"
                  "contribucion" => array:1 [
                    0 => null
                  ]
                  "host" => array:1 [
                    0 => null
                  ]
                ]
              ]
            ]
            5 => array:3 [
              "identificador" => "bib6"
              "etiqueta" => "6"
              "referencia" => array:1 [
                0 => array:3 [
                  "referenciaCompleta" => "Meijer E, Rook M, Tent H, Navis G, van der Jagt EJ, de Jong P, et al. Early renal abnormalities in autosomal dominant polycystic kidney disease. Clin J Am Soc Nephrol 2010;5(6):1091-8. <a href="http://www.ncbi.nlm.nih.gov/pubmed/20413443" target="_blank">[Pubmed]</a>"
                  "contribucion" => array:1 [
                    0 => null
                  ]
                  "host" => array:1 [
                    0 => null
                  ]
                ]
              ]
            ]
            6 => array:3 [
              "identificador" => "bib7"
              "etiqueta" => "7"
              "referencia" => array:1 [
                0 => array:3 [
                  "referenciaCompleta" => "Reiterova J, Obeidova H, Lenicek M, Stekrova J, Merta M, Maixnerova D, et al. Influence of VEGF polymorphism on progression of autosomal dominant polycystic kidney disease. Kidney Blood Press Res 2008;31(6):398-403. <a href="http://www.ncbi.nlm.nih.gov/pubmed/19060482" target="_blank">[Pubmed]</a>"
                  "contribucion" => array:1 [
                    0 => null
                  ]
                  "host" => array:1 [
                    0 => null
                  ]
                ]
              ]
            ]
            7 => array:3 [
              "identificador" => "bib8"
              "etiqueta" => "8"
              "referencia" => array:1 [
                0 => array:3 [
                  "referenciaCompleta" => "Torres VE, Meijer E, Bae KT, Chapman AB, Devuyst O, Gansevoort RT, et al. Rationale and design of the TEMPO (Tolvaptan Efficacy and Safety in Management of Autosomal Dominant Polycystic Kidney Disease and its Outcomes) 3-4 Study. Am J Kidney Dis 2011;57(5):692-9. <a href="http://www.ncbi.nlm.nih.gov/pubmed/21333426" target="_blank">[Pubmed]</a>"
                  "contribucion" => array:1 [
                    0 => null
                  ]
                  "host" => array:1 [
                    0 => null
                  ]
                ]
              ]
            ]
            8 => array:3 [
              "identificador" => "bib9"
              "etiqueta" => "9"
              "referencia" => array:1 [
                0 => array:3 [
                  "referenciaCompleta" => "Irazabal MV, Torres VE, Hogan MC, Glockner J, King BF, Ofstie TG, et al. Short-term effects of tolvaptan on renal function and volume in patients with autosomal dominant polycystic kidney disease. Kidney Int 2011;80(3):295-301. <a href="http://www.ncbi.nlm.nih.gov/pubmed/21544064" target="_blank">[Pubmed]</a>"
                  "contribucion" => array:1 [
                    0 => null
                  ]
                  "host" => array:1 [
                    0 => null
                  ]
                ]
              ]
            ]
            9 => array:3 [
              "identificador" => "bib10"
              "etiqueta" => "10"
              "referencia" => array:1 [
                0 => array:3 [
                  "referenciaCompleta" => "Grantham JJ, Bennett WM,\u{A0}Perrone RD. mTOR inhibitors and autosomal dominant polycystic kidney disease. N Engl J Med 2011;364(3):286-7.\u{A0}Author reply 287-9."
                  "contribucion" => array:1 [
                    0 => null
                  ]
                  "host" => array:1 [
                    0 => null
                  ]
                ]
              ]
            ]
            10 => array:3 [
              "identificador" => "bib11"
              "etiqueta" => "11"
              "referencia" => array:1 [
                0 => array:3 [
                  "referenciaCompleta" => "11 Ruggenenti P, Remuzzi A, Ondei P, Fasolini G, Antiga L, Ene-Iordache B, et al. Safety and efficacy of long-acting somatostatin treatment in autosomal-dominant polycystic kidney disease. Kidney Int 2005;68(1):206-16. <a href="http://www.ncbi.nlm.nih.gov/pubmed/15954910" target="_blank">[Pubmed]</a>"
                  "contribucion" => array:1 [
                    0 => null
                  ]
                  "host" => array:1 [
                    0 => null
                  ]
                ]
              ]
            ]
            11 => array:3 [
              "identificador" => "bib12"
              "etiqueta" => "12"
              "referencia" => array:1 [
                0 => array:3 [
                  "referenciaCompleta" => "Dai B, Liu Y, Mei C, Fu L, Xiong X, Zhang Y, et al. Rosiglitazone attenuates development of polycystic kidney disease and prolongs survival in Han: SPRD rats. Clin Sci (Lond) 2010;119(8):323-33."
                  "contribucion" => array:1 [
                    0 => null
                  ]
                  "host" => array:1 [
                    0 => null
                  ]
                ]
              ]
            ]
            12 => array:3 [
              "identificador" => "bib13"
              "etiqueta" => "13"
              "referencia" => array:1 [
                0 => array:3 [
                  "referenciaCompleta" => "Schrier RW. Hypertension and autosomal dominant polycystic kidney disease. Am J Kidney Dis 2011;57(6):811-3. <a href="http://www.ncbi.nlm.nih.gov/pubmed/21601126" target="_blank">[Pubmed]</a>"
                  "contribucion" => array:1 [
                    0 => null
                  ]
                  "host" => array:1 [
                    0 => null
                  ]
                ]
              ]
            ]
            13 => array:3 [
              "identificador" => "bib14"
              "etiqueta" => "14"
              "referencia" => array:1 [
                0 => array:3 [
                  "referenciaCompleta" => "Schrier RW, Johnson AM, McFann K,\u{A0}Chapman AB. The role of parental hypertension in the frequency and age of diagnosis of hypertension in offspring with autosomal-dominant polycystic kidney disease. Kidney Int 2003;64(5):1792-9. <a href="http://www.ncbi.nlm.nih.gov/pubmed/14531813" target="_blank">[Pubmed]</a>"
                  "contribucion" => array:1 [
                    0 => null
                  ]
                  "host" => array:1 [
                    0 => null
                  ]
                ]
              ]
            ]
            14 => array:3 [
              "identificador" => "bib15"
              "etiqueta" => "15"
              "referencia" => array:1 [
                0 => array:3 [
                  "referenciaCompleta" => "Yium J, Gabow P, Johnson A, Kimberling W, Martinez-Maldonado M. Autosomal dominant polycystic kidney disease in blacks: clinical course and effects of sickle-cell hemoglobin. J Am Soc Nephrol 1994;4(9):1670-4. <a href="http://www.ncbi.nlm.nih.gov/pubmed/8011976" target="_blank">[Pubmed]</a>"
                  "contribucion" => array:1 [
                    0 => null
                  ]
                  "host" => array:1 [
                    0 => null
                  ]
                ]
              ]
            ]
            15 => array:3 [
              "identificador" => "bib16"
              "etiqueta" => "16"
              "referencia" => array:1 [
                0 => array:3 [
                  "referenciaCompleta" => "Belibi FA,\u{A0}Edelstein CL. Unified ultrasonographic diagnostic criteria for polycystic kidney disease. J Am Soc Nephrol 2009;20(1):6-8. <a href="http://www.ncbi.nlm.nih.gov/pubmed/19073819" target="_blank">[Pubmed]</a>"
                  "contribucion" => array:1 [
                    0 => null
                  ]
                  "host" => array:1 [
                    0 => null
                  ]
                ]
              ]
            ]
            16 => array:3 [
              "identificador" => "bib17"
              "etiqueta" => "17"
              "referencia" => array:1 [
                0 => array:3 [
                  "referenciaCompleta" => "Grossfeld GD, Wolf JS Jr, Litwan MS, Hricak H, Shuler CL, Agerter DC, et al. Asymptomatic microscopic hematuria in adults: summary of the AUA best practice policy recommendations. Am Fam Physician 2001;63(6):1145-54. <a href="http://www.ncbi.nlm.nih.gov/pubmed/11277551" target="_blank">[Pubmed]</a>"
                  "contribucion" => array:1 [
                    0 => null
                  ]
                  "host" => array:1 [
                    0 => null
                  ]
                ]
              ]
            ]
            17 => array:3 [
              "identificador" => "bib18"
              "etiqueta" => "18"
              "referencia" => array:1 [
                0 => array:3 [
                  "referenciaCompleta" => "Marín R, de la Sierra A, Armario P, Campo C, Banegas JR, Gorostidi M. 2005 Spanish guidelines in diagnosis and treatment of arterial hypertension. Med Clin (Barc) 2005;125(1):24-34."
                  "contribucion" => array:1 [
                    0 => null
                  ]
                  "host" => array:1 [
                    0 => null
                  ]
                ]
              ]
            ]
            18 => array:3 [
              "identificador" => "bib19"
              "etiqueta" => "19"
              "referencia" => array:1 [
                0 => array:3 [
                  "referenciaCompleta" => "Jones DW,\u{A0}Hall JE. Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure and evidence from new hypertension trials. Hypertension 2004;43(1):1-3. <a href="http://www.ncbi.nlm.nih.gov/pubmed/14676222" target="_blank">[Pubmed]</a>"
                  "contribucion" => array:1 [
                    0 => null
                  ]
                  "host" => array:1 [
                    0 => null
                  ]
                ]
              ]
            ]
            19 => array:3 [
              "identificador" => "bib20"
              "etiqueta" => "20"
              "referencia" => array:1 [
                0 => array:3 [
                  "referenciaCompleta" => "Lobos JM, Royo-Bordonada MA, Brotons C, Álvarez-Sala L, Armario P, Maiques A,\u{A0}et al. European Guidelines on Cardiovascular Disease Prevention in Clinical Practice. CEIPC 2008 Spanish adaptation. Rev Clin Esp 2009;209(6):279-302. <a href="http://www.ncbi.nlm.nih.gov/pubmed/19635253" target="_blank">[Pubmed]</a>"
                  "contribucion" => array:1 [
                    0 => null
                  ]
                  "host" => array:1 [
                    0 => null
                  ]
                ]
              ]
            ]
            20 => array:3 [
              "identificador" => "bib21"
              "etiqueta" => "21"
              "referencia" => array:1 [
                0 => array:3 [
                  "referenciaCompleta" => "Levey AS, Stevens LA, Schmid CH, Zhang YL, Castro AF 3rd, Feldman HI, et al. A new equation to estimate glomerular filtration rate. Ann Intern Med 2009;150(9):604-12. <a href="http://www.ncbi.nlm.nih.gov/pubmed/19414839" target="_blank">[Pubmed]</a>"
                  "contribucion" => array:1 [
                    0 => null
                  ]
                  "host" => array:1 [
                    0 => null
                  ]
                ]
              ]
            ]
            21 => array:3 [
              "identificador" => "bib22"
              "etiqueta" => "22"
              "referencia" => array:1 [
                0 => array:3 [
                  "referenciaCompleta" => "Tokiwa S, Muto S, China T,\u{A0}Horie S. The relationship between renal volume and renal function in autosomal dominant polycystic kidney disease. Clin Exp Nephrol 2011;15(4):539-45. <a href="http://www.ncbi.nlm.nih.gov/pubmed/21431900" target="_blank">[Pubmed]</a>"
                  "contribucion" => array:1 [
                    0 => null
                  ]
                  "host" => array:1 [
                    0 => null
                  ]
                ]
              ]
            ]
            22 => array:3 [
              "identificador" => "bib23"
              "etiqueta" => "23"
              "referencia" => array:1 [
                0 => array:3 [
                  "referenciaCompleta" => "Dicks E, Ravani P, Langman D, Davidson WS, Pei Y,\u{A0}Parfrey PS. Incident renal events and risk factors in autosomal dominant polycystic kidney disease: a population and family-based cohort followed for 22 years. Clin J Am Soc Nephrol 2006;1(4):710-7. <a href="http://www.ncbi.nlm.nih.gov/pubmed/17699277" target="_blank">[Pubmed]</a>"
                  "contribucion" => array:1 [
                    0 => null
                  ]
                  "host" => array:1 [
                    0 => null
                  ]
                ]
              ]
            ]
            23 => array:3 [
              "identificador" => "bib24"
              "etiqueta" => "24"
              "referencia" => array:1 [
                0 => array:3 [
                  "referenciaCompleta" => "Chapman AB. Approaches to testing new treatments in autosomal dominant polycystic kidney disease: insights from the CRISP and HALT-PKD studies. Clin J Am Soc Nephrol 2008;3(4):1197-204. <a href="http://www.ncbi.nlm.nih.gov/pubmed/18579674" target="_blank">[Pubmed]</a>"
                  "contribucion" => array:1 [
                    0 => null
                  ]
                  "host" => array:1 [
                    0 => null
                  ]
                ]
              ]
            ]
            24 => array:3 [
              "identificador" => "bib25"
              "etiqueta" => "25"
              "referencia" => array:1 [
                0 => array:3 [
                  "referenciaCompleta" => "Chapman AB, Guay-Woodford LM, Grantham JJ, Torres VE, Bae KT, Baumgarten DA, et al. Renal structure in early autosomal-dominant polycystic kidney disease (ADPKD): The Consortium for Radiologic Imaging Studies of Polycystic Kidney Disease (CRISP) cohort. Kidney Int 2003;64(3):1035-45. <a href="http://www.ncbi.nlm.nih.gov/pubmed/12911554" target="_blank">[Pubmed]</a>"
                  "contribucion" => array:1 [
                    0 => null
                  ]
                  "host" => array:1 [
                    0 => null
                  ]
                ]
              ]
            ]
            25 => array:3 [
              "identificador" => "bib26"
              "etiqueta" => "26"
              "referencia" => array:1 [
                0 => array:3 [
                  "referenciaCompleta" => "King BF, Reed JE, Bergstralh EJ, Sheedy PF, Torres VE. Quantification and longitudinal trends of kidney, renal cysts and renal parenchyma volumes in Autosomal dominant polycystic kidney disease. J Am Soc Nephrol 2000;11(8):1505-11. <a href="http://www.ncbi.nlm.nih.gov/pubmed/10906164" target="_blank">[Pubmed]</a>"
                  "contribucion" => array:1 [
                    0 => null
                  ]
                  "host" => array:1 [
                    0 => null
                  ]
                ]
              ]
            ]
            26 => array:3 [
              "identificador" => "bib27"
              "etiqueta" => "27"
              "referencia" => array:1 [
                0 => array:3 [
                  "referenciaCompleta" => "Chapman, AB,\u{A0}Wei W. Imaging approaches to patients with polycystic kidney disease. Semin Nephrol 2011;31(3):237-44. <a href="http://www.ncbi.nlm.nih.gov/pubmed/21784272" target="_blank">[Pubmed]</a>"
                  "contribucion" => array:1 [
                    0 => null
                  ]
                  "host" => array:1 [
                    0 => null
                  ]
                ]
              ]
            ]
            27 => array:3 [
              "identificador" => "bib28"
              "etiqueta" => "28"
              "referencia" => array:1 [
                0 => array:3 [
                  "referenciaCompleta" => "Antiga L, Piccinelli M, Fasolini G, Ene-Iordache B, Ondei P, Bruno S, et al. Computed tomography evaluation of autosomal dominant polycystic kidney disease progression: a progress report. Clin J Am Soc Nephrol 2006;1(4):754-60. <a href="http://www.ncbi.nlm.nih.gov/pubmed/17699283" target="_blank">[Pubmed]</a>"
                  "contribucion" => array:1 [
                    0 => null
                  ]
                  "host" => array:1 [
                    0 => null
                  ]
                ]
              ]
            ]
            28 => array:3 [
              "identificador" => "bib29"
              "etiqueta" => "29"
              "referencia" => array:1 [
                0 => array:3 [
                  "referenciaCompleta" => "Kazancioglu R, Ecder T, Altintepe L, Altiparmak MR, Tuglular S, Uyanik A, et al. Demographic and clinical characteristics of patients with autosomal dominant polycystic kidney disease: a multicenter experience. Nephron Clin Pract 2011;117(3):c270-5. <a href="http://www.ncbi.nlm.nih.gov/pubmed/20847569" target="_blank">[Pubmed]</a>"
                  "contribucion" => array:1 [
                    0 => null
                  ]
                  "host" => array:1 [
                    0 => null
                  ]
                ]
              ]
            ]
            29 => array:3 [
              "identificador" => "bib30"
              "etiqueta" => "30"
              "referencia" => array:1 [
                0 => array:3 [
                  "referenciaCompleta" => "Ecder T, Schrier RW. Hypertension in autosomal-dominant polycystic kidney disease: early occurrence and unique aspects. J Am Soc Nephrol 2001;12(1):194-200. <a href="http://www.ncbi.nlm.nih.gov/pubmed/11134267" target="_blank">[Pubmed]</a>"
                  "contribucion" => array:1 [
                    0 => null
                  ]
                  "host" => array:1 [
                    0 => null
                  ]
                ]
              ]
            ]
            30 => array:3 [
              "identificador" => "bib31"
              "etiqueta" => "31"
              "referencia" => array:1 [
                0 => array:3 [
                  "referenciaCompleta" => "Ahmed ER, Tashkandi MA, Nahrir S, Maulana A. Retrospective analysis of factors affecting the progression of chronic renal failure in adult polycystic kidney disease. Saudi J Kidney Dis Transpl 2006;17(4):511-5. <a href="http://www.ncbi.nlm.nih.gov/pubmed/17186685" target="_blank">[Pubmed]</a>"
                  "contribucion" => array:1 [
                    0 => null
                  ]
                  "host" => array:1 [
                    0 => null
                  ]
                ]
              ]
            ]
            31 => array:3 [
              "identificador" => "bib32"
              "etiqueta" => "32"
              "referencia" => array:1 [
                0 => array:3 [
                  "referenciaCompleta" => "Idrizi A, Barbullushi M, Strakosha A, Kodra S, Thereska N, Zaimi E, et al. The relation of hypertension, renal function and cardiovascular events in autosomal dominant polycystic kidney disease. G Ital Nefrol 2007;24(6):595-9. <a href="http://www.ncbi.nlm.nih.gov/pubmed/18278763" target="_blank">[Pubmed]</a>"
                  "contribucion" => array:1 [
                    0 => null
                  ]
                  "host" => array:1 [
                    0 => null
                  ]
                ]
              ]
            ]
            32 => array:3 [
              "identificador" => "bib33"
              "etiqueta" => "33"
              "referencia" => array:1 [
                0 => array:3 [
                  "referenciaCompleta" => "Patch C, Charlton J, Roderick PJ,\u{A0}Gulliford MC. Use of antihypertensive medications and mortality of patients with autosomal dominant polycystic kidney disease: a population-based study. Am J Kidney Dis 2011;57(6):856-62. <a href="http://www.ncbi.nlm.nih.gov/pubmed/21458899" target="_blank">[Pubmed]</a>"
                  "contribucion" => array:1 [
                    0 => null
                  ]
                  "host" => array:1 [
                    0 => null
                  ]
                ]
              ]
            ]
            33 => array:3 [
              "identificador" => "bib34"
              "etiqueta" => "34"
              "referencia" => array:1 [
                0 => array:3 [
                  "referenciaCompleta" => "Orskov B, Romming Sorensen V, Feldt-Rasmussen B,\u{A0}Strandgaard S. Improved prognosis in patients with autosomal dominant polycystic kidney disease in Denmark. Clin J Am Soc Nephrol 2010;5(11):2034-9. <a href="http://www.ncbi.nlm.nih.gov/pubmed/20671227" target="_blank">[Pubmed]</a>"
                  "contribucion" => array:1 [
                    0 => null
                  ]
                  "host" => array:1 [
                    0 => null
                  ]
                ]
              ]
            ]
            34 => array:3 [
              "identificador" => "bib35"
              "etiqueta" => "35"
              "referencia" => array:1 [
                0 => array:3 [
                  "referenciaCompleta" => "Nakamura T, Sato E, Fujiwara N, Kawagoe Y, Yamada S, Ueda Y, et al. Changes in Urinary Albumin Excretion, Inflammatory and Oxidative Stress Markers in ADPKD Patients with Hypertension. Am J Med Sci 2012;343(1):46-51. <a href="http://www.ncbi.nlm.nih.gov/pubmed/21760473" target="_blank">[Pubmed]</a>"
                  "contribucion" => array:1 [
                    0 => null
                  ]
                  "host" => array:1 [
                    0 => null
                  ]
                ]
              ]
            ]
            35 => array:3 [
              "identificador" => "bib36"
              "etiqueta" => "36"
              "referencia" => array:1 [
                0 => array:3 [
                  "referenciaCompleta" => "Sans L, Roca-Cuchars A, Torra R, Calero F, Arias P, Ballarin J, et al. Relationship between kidney size and blood pressure profile in patients with Autosomal dominant polycystic kidney disease without renal failure. Nefrologia 2010;30(5):567-72. <a href="http://www.ncbi.nlm.nih.gov/pubmed/20882096" target="_blank">[Pubmed]</a>"
                  "contribucion" => array:1 [
                    0 => null
                  ]
                  "host" => array:1 [
                    0 => null
                  ]
                ]
              ]
            ]
            36 => array:3 [
              "identificador" => "bib37"
              "etiqueta" => "37"
              "referencia" => array:1 [
                0 => array:3 [
                  "referenciaCompleta" => "Cadnapaphornchai MA, McFann K, Strain JD, Masoumi A, Schrier RW. Increased left\u{A0}ventricular mass in children with Autosomal dominant polycystic kidney disease and borderline\u{A0}hypertension. Kidney Int 2008;74(9):1192-6. <a href="http://www.ncbi.nlm.nih.gov/pubmed/18716604" target="_blank">[Pubmed]</a>"
                  "contribucion" => array:1 [
                    0 => null
                  ]
                  "host" => array:1 [
                    0 => null
                  ]
                ]
              ]
            ]
            37 => array:3 [
              "identificador" => "bib38"
              "etiqueta" => "38"
              "referencia" => array:1 [
                0 => array:3 [
                  "referenciaCompleta" => "Agarwal R. Blood pressure components and the risk for end-stage renal disease and death in chronic kidney disease. Clin J Am Soc Nephrol 2009;4(4):830-7. <a href="http://www.ncbi.nlm.nih.gov/pubmed/19339424" target="_blank">[Pubmed]</a>"
                  "contribucion" => array:1 [
                    0 => null
                  ]
                  "host" => array:1 [
                    0 => null
                  ]
                ]
              ]
            ]
            38 => array:3 [
              "identificador" => "bib39"
              "etiqueta" => "39"
              "referencia" => array:1 [
                0 => array:3 [
                  "referenciaCompleta" => "Wuhl E, Schaefer F. Managing kidney disease with blood-pressure control. Nat Rev Nephrol 2011;7(8):434-44. <a href="http://www.ncbi.nlm.nih.gov/pubmed/21691318" target="_blank">[Pubmed]</a>"
                  "contribucion" => array:1 [
                    0 => null
                  ]
                  "host" => array:1 [
                    0 => null
                  ]
                ]
              ]
            ]
            39 => array:3 [
              "identificador" => "bib40"
              "etiqueta" => "40"
              "referencia" => array:1 [
                0 => array:3 [
                  "referenciaCompleta" => "Wenzel RR. Renal protection in hypertensive patients: selection of antihypertensive therapy. Drugs 2005;65 Suppl 2:29-39. <a href="http://www.ncbi.nlm.nih.gov/pubmed/16398060" target="_blank">[Pubmed]</a>"
                  "contribucion" => array:1 [
                    0 => null
                  ]
                  "host" => array:1 [
                    0 => null
                  ]
                ]
              ]
            ]
            40 => array:3 [
              "identificador" => "bib41"
              "etiqueta" => "41"
              "referencia" => array:1 [
                0 => array:3 [
                  "referenciaCompleta" => "Chapman AB, Torres VE, Perrone RD, Steinman TI, Bae KT, Miller JP, et al. The HALT polycystic kidney disease trials: design and implementation. Clin J Am Soc Nephrol 2010;5(1):102-9. <a href="http://www.ncbi.nlm.nih.gov/pubmed/20089507" target="_blank">[Pubmed]</a>"
                  "contribucion" => array:1 [
                    0 => null
                  ]
                  "host" => array:1 [
                    0 => null
                  ]
                ]
              ]
            ]
            41 => array:3 [
              "identificador" => "bib42"
              "etiqueta" => "42"
              "referencia" => array:1 [
                0 => array:3 [
                  "referenciaCompleta" => "Sarnak MJ,\u{A0}Astor BC. Implications of Proteinuria: CKD progression and cardiovascular outcomes. Adv Chronic Kidney Dis 2011;18(4):258-66. <a href="http://www.ncbi.nlm.nih.gov/pubmed/21782132" target="_blank">[Pubmed]</a>"
                  "contribucion" => array:1 [
                    0 => null
                  ]
                  "host" => array:1 [
                    0 => null
                  ]
                ]
              ]
            ]
            42 => array:3 [
              "identificador" => "bib43"
              "etiqueta" => "43"
              "referencia" => array:1 [
                0 => array:3 [
                  "referenciaCompleta" => "Hateboer N, van Dijk MA, Bogdanova N, Coto E, Saggar-Malik AK, San Millan JL, et al. Comparison of phenotypes of polycystic kidney disease types 1 and 2. European PKD1-PKD2 Study Group. Lancet 1999;353(9147):103-7."
                  "contribucion" => array:1 [
                    0 => null
                  ]
                  "host" => array:1 [
                    0 => null
                  ]
                ]
              ]
            ]
            43 => array:3 [
              "identificador" => "bib44"
              "etiqueta" => "44"
              "referencia" => array:1 [
                0 => array:3 [
                  "referenciaCompleta" => "Grantham JJ. Clinical practice. Autosomal dominant polycystic kidney disease. N Engl J Med 2008;359(14):1477-85. <a href="http://www.ncbi.nlm.nih.gov/pubmed/18832246" target="_blank">[Pubmed]</a>"
                  "contribucion" => array:1 [
                    0 => null
                  ]
                  "host" => array:1 [
                    0 => null
                  ]
                ]
              ]
            ]
            44 => array:3 [
              "identificador" => "bib45"
              "etiqueta" => "45"
              "referencia" => array:1 [
                0 => array:3 [
                  "referenciaCompleta" => "Torra R, Badenas C, Pérez-Oller L, Luis J, Millán S, Nicolau C. Increased prevalence of polycystic kidney disease type 2 among elderly polycystic patients. Am J Kidney Dis 2000;36(4):728-34. <a href="http://www.ncbi.nlm.nih.gov/pubmed/11007674" target="_blank">[Pubmed]</a>"
                  "contribucion" => array:1 [
                    0 => null
                  ]
                  "host" => array:1 [
                    0 => null
                  ]
                ]
              ]
            ]
            45 => array:3 [
              "identificador" => "bib46"
              "etiqueta" => "46"
              "referencia" => array:1 [
                0 => array:3 [
                  "referenciaCompleta" => "Barua M, Cil O, Paterson AD, Wang K, He N, Dicks E, et al. Family history of renal disease severity predicts the mutated gene in ADPKD. J Am Soc Nephrol 2009;20(8):1833-8. <a href="http://www.ncbi.nlm.nih.gov/pubmed/19443633" target="_blank">[Pubmed]</a>"
                  "contribucion" => array:1 [
                    0 => null
                  ]
                  "host" => array:1 [
                    0 => null
                  ]
                ]
              ]
            ]
            46 => array:3 [
              "identificador" => "bib47"
              "etiqueta" => "47"
              "referencia" => array:1 [
                0 => array:3 [
                  "referenciaCompleta" => "Hosoya T, Ichida K, Tabe A,\u{A0}Sakai O. A study of uric acid metabolism and gouty arthritis in patients with polycystic kidney. Nippon Jinzo Gakkai Shi 1993;35(1):43-8. <a href="http://www.ncbi.nlm.nih.gov/pubmed/8336399" target="_blank">[Pubmed]</a>"
                  "contribucion" => array:1 [
                    0 => null
                  ]
                  "host" => array:1 [
                    0 => null
                  ]
                ]
              ]
            ]
            47 => array:3 [
              "identificador" => "bib48"
              "etiqueta" => "48"
              "referencia" => array:1 [
                0 => array:3 [
                  "referenciaCompleta" => "Kuo CF, Luo SF, See LC, Ko YS, Chen YM, Hwang JS, et al. Hyperuricaemia and accelerated reduction in renal function. Scand J Rheumatol 2011;40(2):116-21. <a href="http://www.ncbi.nlm.nih.gov/pubmed/20868309" target="_blank">[Pubmed]</a>"
                  "contribucion" => array:1 [
                    0 => null
                  ]
                  "host" => array:1 [
                    0 => null
                  ]
                ]
              ]
            ]
            48 => array:3 [
              "identificador" => "bib49"
              "etiqueta" => "49"
              "referencia" => array:1 [
                0 => array:3 [
                  "referenciaCompleta" => "Feig DI. Uric acid: a novel mediator and marker of risk in chronic kidney disease? Curr Opin Nephrol Hypertens 2009;18(6):526-30. <a href="http://www.ncbi.nlm.nih.gov/pubmed/19654543" target="_blank">[Pubmed]</a>"
                  "contribucion" => array:1 [
                    0 => null
                  ]
                  "host" => array:1 [
                    0 => null
                  ]
                ]
              ]
            ]
            49 => array:3 [
              "identificador" => "bib50"
              "etiqueta" => "50"
              "referencia" => array:1 [
                0 => array:3 [
                  "referenciaCompleta" => "Goicoechea M, de Vinuesa SG, Verdalles U, Ruiz-Caro C, Ampuero J, Rincon A, et al. Effect of allopurinol in chronic kidney disease progression and cardiovascular risk. Clin J Am Soc Nephrol 2010;5(8):1388-93. <a href="http://www.ncbi.nlm.nih.gov/pubmed/20538833" target="_blank">[Pubmed]</a>"
                  "contribucion" => array:1 [
                    0 => null
                  ]
                  "host" => array:1 [
                    0 => null
                  ]
                ]
              ]
            ]
            50 => array:3 [
              "identificador" => "bib51"
              "etiqueta" => "51"
              "referencia" => array:1 [
                0 => array:3 [
                  "referenciaCompleta" => "van Dijk MA, Kamper AM, van Veen S, Souverijn JH,\u{A0}Blauw GJ. Effect of simvastatin on renal function in autosomal dominant polycystic kidney disease. Nephrol Dial Transplant 2001;16(11):2152-7. <a href="http://www.ncbi.nlm.nih.gov/pubmed/11682660" target="_blank">[Pubmed]</a>"
                  "contribucion" => array:1 [
                    0 => null
                  ]
                  "host" => array:1 [
                    0 => null
                  ]
                ]
              ]
            ]
          ]
        ]
      ]
    ]
  ]
  "idiomaDefecto" => "en"
  "url" => "/20132514/0000003200000002/v0_201502091616/X2013251412000914/v0_201502091617/en/main.assets"
  "Apartado" => array:4 [
    "identificador" => "35441"
    "tipo" => "SECCION"
    "en" => array:2 [
      "titulo" => "Originals"
      "idiomaDefecto" => true
    ]
    "idiomaDefecto" => "en"
  ]
  "PDF" => "https://static.elsevier.es/multimedia/20132514/0000003200000002/v0_201502091616/X2013251412000914/v0_201502091617/en/P1-E534-S3437-A11177-EN.pdf?idApp=UINPBA000064&text.app=https://revistanefrologia.com/"
  "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/X2013251412000914?idApp=UINPBA000064"
]

Article information

ISSN: 20132514
Original language: English

DOI:10.3265/Nefrologia.pre2011.Dec.11177

The statistics are updated each day

Year/Month	Html	Pdf	Total

2024 November	6	11	17
2024 October	87	43	130
2024 September	312	28	340
2024 August	72	58	130
2024 July	69	39	108
2024 June	78	46	124
2024 May	86	42	128
2024 April	52	39	91
2024 March	60	29	89
2024 February	41	35	76
2024 January	30	31	61
2023 December	40	34	74
2023 November	49	51	100
2023 October	43	41	84
2023 September	41	33	74
2023 August	42	24	66
2023 July	47	28	75
2023 June	62	26	88
2023 May	75	28	103
2023 April	39	13	52
2023 March	44	20	64
2023 February	36	15	51
2023 January	83	28	111
2022 December	49	34	83
2022 November	49	41	90
2022 October	43	43	86
2022 September	42	45	87
2022 August	48	48	96
2022 July	49	48	97
2022 June	39	32	71
2022 May	37	28	65
2022 April	56	50	106
2022 March	73	52	125
2022 February	62	48	110
2022 January	95	32	127
2021 December	80	37	117
2021 November	56	35	91
2021 October	102	38	140
2021 September	66	39	105
2021 August	52	53	105
2021 July	56	32	88
2021 June	37	18	55
2021 May	44	46	90
2021 April	84	61	145
2021 March	43	45	88
2021 February	36	14	50
2021 January	49	16	65
2020 December	37	17	54
2020 November	36	21	57
2020 October	21	21	42
2020 September	28	5	33
2020 August	43	14	57
2020 July	50	15	65
2020 June	49	9	58
2020 May	56	12	68
2020 April	41	19	60
2020 March	60	18	78
2020 February	44	14	58
2020 January	37	21	58
2019 December	57	24	81
2019 November	69	26	95
2019 October	50	19	69
2019 September	87	28	115
2019 August	44	17	61
2019 July	67	31	98
2019 June	76	17	93
2019 May	83	13	96
2019 April	102	30	132
2019 March	66	20	86
2019 February	85	30	115
2019 January	84	25	109
2018 December	165	39	204
2018 November	110	23	133
2018 October	175	21	196
2018 September	137	13	150
2018 August	122	16	138
2018 July	107	14	121
2018 June	75	11	86
2018 May	93	17	110
2018 April	140	12	152
2018 March	105	14	119
2018 February	60	10	70
2018 January	87	6	93
2017 December	79	15	94
2017 November	88	14	102
2017 October	82	8	90
2017 September	69	18	87
2017 August	63	16	79
2017 July	67	12	79
2017 June	87	13	100
2017 May	97	20	117
2017 April	66	11	77
2017 March	59	9	68
2017 February	71	5	76
2017 January	51	12	63
2016 December	84	11	95
2016 November	129	17	146
2016 October	165	22	187
2016 September	323	7	330
2016 August	316	9	325
2016 July	306	10	316
2016 June	168	0	168
2016 May	163	0	163
2016 April	134	0	134
2016 March	106	0	106
2016 February	150	0	150
2016 January	148	0	148
2015 December	170	0	170
2015 November	117	0	117
2015 October	119	0	119
2015 September	97	0	97
2015 August	95	0	95
2015 July	92	0	92
2015 June	42	0	42
2015 May	47	0	47
2015 April	8	0	8

Show all

Indexed in:

Follow us:

Statistics

Indexed in:

Follow us:

Statistics

Subscribe to our newsletter